This is a preview of subscription content, log in via an institution to check access.
Preview
Unable to display preview. Download preview PDF.
References
Abrahamsson S, Bergström S, Samuelsson B (1962) The absolute configuration of prostaglandin F2–1. Proc Chem Soc:332
Adaikan PG, Lau LC, Tai MY, Karim SMM (1983) Inhibition of platelet aggregation with intravenous and oral administration of a carboprostacyclin analogue, 15-cyclopentyl-θ-pentanor-5(E)-carbacyclin (ONO 41483) in man. Prostaglandins Leukotrienes Med 10:53–64
Adaikan PG, Karim SMM, Lau LC, Tai MY, Kottegoda SR (1984) Inhibition of platelet aggregation and antagonism of vasopressin-induced ECG changes in primates by a carboprostacyclin analogue, ZK 36374. Thromb Res 33:333–340
Adams SS, Burrows CA, Skeldon N, Yates DB (1977) Inhibition of prostaglandin synthesis and leucocyte migration by flurbiprofen. Curr Med Res Opin 5:11–16
Aehringhaus U, Wölbling RH, König W, Patrono C, Peskar BM, Peskar BA (1982) Release of leukotrience C4 from human polymorphonuclear leukocytes as determined by radioimmunoassay. FEBS Lett 146:111–114
Aehringhaus U, Peskar BA, Wittenberg HR, Wölbling RH (1983) Effect of inhibition of synthesis and receptor antagonism of SRS-A in cardiac anaphylaxis. Br J Pharmacol 80:73–80
Aehringhaus U, Dembinska-Kiéc A, Peskar BA (1984) Effects of exogenous prostaglandins on the release of leukotriene C4-like immunoreactivity and on coronary flow in indomethacin-treated anaphylactic guinea pig hearts. Naunyn-Schmiedebergs Arch Pharmacol 326:368–374
Ahumada GG, Sobel BE, Needleman P (1980) Synthesis of prostaglandins by cultured rat heart myocytes and cardiac mesenchymal cells. J Mol Cell Cardiol 12:685–700
Aiken JW, Shebuski RJ (1980) Comparison in anaesthetized dogs of the anti-aggregatory and hemodynamic effects of prostacyclin and a chemically stable prostacyclin analog, 6a-carba-PGI2 (carbacyclin). Prostaglandins 19:629–643
Aiken JW, Gorman RR, Shebuski RJ (1979) Prevention of blockade of partially obstructed coronary arteries with prostacyclin correlates with inhibition of platelet aggregation. Prostaglandins 17:483–494
Aiken JW, Shebuski RJ, Miller OV, Gorman RR (1981) Endogenous prostacyclin contributes to the efficacy of a thromboxane synthetase inhibitor for preventing coronary artery thrombosis. J Pharmacol Exp Ther 219:299–308
Allan G, Levi R (1980) The cardiac effects of prostaglandins and their modification by the prostaglandin antagonist N-0164. J Pharmacol Exp Ther 214:45–49
Allan G, Levi R (1981) Thromboxane and prostacyclin release during cardiac immediate hypersensitivity reactions in vitro. J Pharmacol Exp Ther 217:157–161
Anderson WH, Mohammad SF, Chuang HYK, Mason RG (1980) Heparin potentiates synthesis of thromboxane A2 in human platelets. Adv Prostaglandin Thromboxane Res 6:287–291
Änggård E, Larsson C, Samuelsson B (1971) The distribution of 15-hydroxyprostaglandin dehydrogenase and prostaglandin Δ13-reductase in tissues of the swine. Acta Physiol Scand 81:396–404
Anhut H, Bernauer W, Peskar BA (1977) Radioimmunological determination of thromboxane release in cardiac anaphylaxis. Eur J Pharmacol 44:85–88
Anhut H, Bernauer W, Peskar BA (1978a) Pharmacological modification of thromboxane and prostaglandin release in cardiac anaphylaxis. Prostaglandins 15:889–900
Anhut H, Peskar BA, Bernauer W (1978b) Release of 15-keto-13,14-dihydro-thromboxane B2 and prostaglandin D2 during anaphylaxis as measured by radioimmunoassay. Naunyn-Schmiedebergs Arch Pharmacol 305:247–252
Anturane Reinfarction Italian Study Group (1982) Sulphinpyrazone in post-myocardial infarction. Lancet 1:237–242
Anturane Reinfarction Trial Research Group (1978) Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. The anturane reinfarction trial. N Engl J Med 298:289–295
Anturane Reinfarction Trial Research Group (1980) Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 302:250–256
Armstrong JM, Chapple D, Dusting GJ, Hughes R, Moncada S, Vane JR (1977) Cardiovascular actions of prostacyclin (PGI2) in chloralose anaesthetized dogs. Br J Pharmacol 61:136P
Arnoux B, Duval D, Benveniste J (1980) Release of platelet-activating factor (PAF-acether) from alveolar macrophages by the calcium ionophore A 23187 and phagocytosis. Eur J Clin Invest 10:437–441
Aspirin Myocardial Infarction Study Research Group (1980) A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 243:661–669
Auer J (1911) Lethal cardiac anaphylaxis in the rabbit. J Exp Med 14:476–496
Auer J, Lewis PA (1910) The physiology of the immediate reaction of anaphylaxis in the guinea pig. J Exp Med 12:151–175
Augstein J, Farmer JR, Lee TB, Sheard P, Tattersall ML (1973) Selective inhibition of slow reacting substance of anaphylaxis. Nature (New Biol) 245:215–217
Austen K (1965) Systemic anaphylaxis in man. JAMA 12:116–118
Austen K (1978) The anaphylactic syndrome. In: Samter M (ed) Immunological diseases, vol 2, 3rd edn. Little Brown, Boston, pp 885–899
Bakhle YS (1983) Synthesis and catabolism of cyclo-oxygenase products. Br Med Bull 39:214–218
Baraka A, Sfeir S (1980) Anaphylactic cardiac arrest in a parturient. JAMA 243:1745–1746
Beitz J, Förster W (1980) Influence of human low density and high density lipoprotein cholesterol on the in vitro prostaglandin I2 synthetase activity. Biochim Biophys Acta 620:352–355
Belch JJF, Greer I, McLaren M, Saniabadi AR, Miller S, Sturrock RD, Forbes CD (1984) The effects of intravenous ZK36-374, a stable prostacyclin analogue, on human volunteers. Prostaglandins 28:67–77
Benveniste J (1974) Platelet-activating factor, a new mediator of anaphylaxis and immune complex deposition from rabbit and human basophils. Nature 249:581–582
Benveniste J, Henson PM, Cochrane CG (1972) Leukocyte-dependent histamine release from rabbit platelets: the role of IgE, basophils and a platelet-activating factor. J Exp Med 136:1356–1377
Benveniste J, Le Couedic JP, Kamoun P (1975) Aggregation of human platelets by platelet-activating factor. Lancet 1:344–345
Benveniste J, Le Couedic JP, Polonsky J, Tence M (1977) Structural analysis of purified platelet-activating factor by lipases. Nature 269:170–171
Benveniste J, Boullet C, Brink C, Labat C (1983) The actions of Paf-acether (platelet-activating factor) on guinea-pig isolated heart preparations. Br J Pharmacol 80:81–83
Berger HJ, Zaret BL, Speroff L, Cohen LS, Wolfson S (1976) Regional cardiac prostaglandin release during myocardial ischemia in anaesthetized dogs. Circ Res 38:566–571
Bergman G, Daly K, Atkinson L, Rothman M, Richardson PJ, Jackson G, Jewitt DE (1981) Prostacyclin: haemodynamic and metabolic effects in patients with coronary artery disease. Lancet 1:569–572
Bergström S, Sjövall J (1960a) The isolation of prostaglandin F from sheep prostate glands. Acta Chem Scand 14:1693–1700
Bergström S, Sjövall J (1960b) The isolation of prostaglandin E from sheep prostate glands. Acta Chem Scand 14:1701:1705
Bergström S, Ryhage R, Samuelsson B, Sjövall J (1963) Prostaglandins and related factors. The structure of prostaglandin E1, F1α and F1β. J Biol Chem 238:3555–3564
Bergström S, Danielsson H, Samuelsson B (1964) The enzymatic formation of prostaglandin E2 from arachidonic acid. Biochim Biophys Acta 90:207–210
Bergström S, Carlson LA, Weeks JR (1968) The prostaglandins: a family of biologically active lipids. Phrmacol Rev 20:1–48
Bernreiter M (1959) Electrocardiogram of patient in anaphylactic shock. JAMA 170:1628–1630
Bessin P, Bonnet J, Apffel D, Soulard C, Desgroux L, Pelas I, Benveniste J (1983) Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol 86:403–413
Best LC, Martin TJ, Russell RGG, Preston FE (1977) Prostacyclin increases cyclic AMP levels and adenylate cyclase activity in platelets. Nature 267:850–852
Binder MJ, Gunderson HJ, Cannon J, Rosove L (1950) Electrocardiographic changes associated with allergic reactions to penicillin. Am Heart J 40:940–944
Björk J, Hedqvist P, Arfors KE (1982) Increase in vascular permeability induced by leukotriene B4 and the role of polymorphonuclear leukocytes. Inflammation 6:189–200
Blackwell GJ, Flower RJ (1983) Inhibition of phospholipase. Br Med Bull 39:260–264
Blackwell GJ, Flower RJ, Russell-Smith N, Salmon JA, Thorogood PB, Vane JR (1978) Prostacyclin is produced in whole blood. Br J Pharmacol 64:436P
Blackwell GJ, Carnuccio R, DiRosa M, Flower RJ, Parente L, Persico P (1980) Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature 287:147–149
Blaskó G, Berentey E, Harsányi A, Sas G (1983) Intracoronarily administered prostacyclin and streptokinase for treatment of myocardial infarction. Adv Prostaglandin Thromboxane Leukotrienes Res 11:385–390
Block AJ, Feinberg H, Herbacynska-Cedro K, Vane JR (1975) Anoxia-induced release of prostaglandins in rabbit isolated hearts. Circ Res 36:34–42
Bolli R, Goldstein RE, Davenport N, Epstein SE (1981) Influence of sulfinpyrazone and naproxen on infarct size in the dog. Am J Cardiol 47:841–847
Bolton HS, Chanderbhan R, Bryant RW, Bailey JM, Weglicki WB, Vahouny GV (1980) Prostaglandin synthesis by adult heart myocytes. J Mol Cell Cardiol 12:1287–1298
Bonow RO, Lipson LC, Sheehan FH, Capurro NL, Isner JM, Roberts WC, Goldstein RE, Epstein SE (1981) Lack of effect of aspirin on myocardial infarct size in the dog. Am J Cardiol 47:258–264
Booth BH, Patterson R (1970) Electrocardiographic changes during human anaphylaxis. JAMA 211:627–631
Borgeat P, Samuelsson B (1979a) Arachidonic acid metabolism in polymorphonuclear leukocytes: Effects of ionophore A23187. Proc Natl Acad Sci USA 76:2148–2152
Borgeat P, Samuelsson B (1979b) Metabolism of arachidonic acid in polymorphonuclear leukocytes: structure analysis of novel hydroxylated compounds. J Biol Chem 254:7865–7869
Borgeat P, Hamberg M, Samuelsson B (1976) Transformation of arachidonic acid and homo-γ-linolenic acid by rabbit polymorphonuclear leukocytes. Monohydroxy acids from novel lipoxygenase. J Biol Chem 251:7816–7820
Born GV (1962) Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 194:927–929
Boston Collaborative Drug Surveillance Group (1974) Regular aspirin intake and acute myocardial infarction. Br Med J 1:440–443
Boyd LM, Ezra D, Feuerstein G, Goldstein RE (1983) Effects of FPL-55712 or indomethacin on leukotriene-induced coronary constriction in the intact pig heart. Eur J Pharmacol 89:307–311
Breddin K, Loew D, Lechner K, Überla K, Walter E (1979) Secondary prevention of myocardial infarction. Comparison of acetylsalicylic acid, phenprocoumon and placebo. A multicenter two-year prospective study. Thromb Haemost 41:225–236
Bristow MR, Ginsburg R, Kantrowitz NE, Baim DS, Rosenbaum JT (1982) Coronary spasm associated with urticaria: Report of a case mimicking anaphylaxis. Clin Cardiol (Lond) 5:238–240
Brocklehurst WE (1953) Occurrence of an unidentified substance during anaphylaxic shock in cavy lung. J Physiol 120:16P–17P
Brocklehurst WE (1960) The release of histamine and formation of a slow-reacting substance (SRS-A) during anaphylactic shock. J Physiol 151:416–435
Brox JH, Nordøy A (1983) The effect of polyunsaturated fatty acids on endothelial cells and their production of prostacyclin, thromboxane and platelet inhibitory activity. Thromb Haemost 50:762–767
Brox JH, Killie JE, Gunnes S, Nordøy A (1981) The effect of cod liver oil and corn oil on platelets and vessel wall in man. Thromb Haemost 46:606–611
Bulkley BH, Roberts WC (1974) Steroid therapy during acute myocardial infarction: A case of delayed healing and ventricular aneurysm. Am J Med 56:244–250
Bunting S, Gryglewski R, Moncada S, Vane JR (1976) Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac arteries and inhibits platelet aggregation. Prostaglandins 12:897–913
Bunting S, Moncada S, Vane JR (1983) The prostacyclin-thromboxane A2 balance: pathophysiological and therapeutic implications. Br Med Bull 39:271–276
Burke JA, Levi R (1980) Slow reacting substance of anaphylaxis (SRS-A): Direct and indirect cardiac effects. Fed Proc 39:389
Burke JA, Levi R, Corey EJ (1981) Cardiovascular effects of pure synthetic leukotrienes C and D. Fed Proc 40:1015
Burke JA, Levi R, Guo ZG, Corey EJ (1982a) Leukotriene C4, D4 and E4: Effects on human and guinea-pig cardiac preparations in vitro. J Pharmacol Exp Ther 221:235–241
Burke JA, Levi R, Hanahan DJ, Pinckard RN (1982b) Cardiac effects of acethyl glyceryl ether phosphorylcholine. Fed Proc 41:823
Burke SE, DiCola G, Lefer AM (1983a) Protection of ischemic cat myocardium by CGS-13080, a selective potent thromboxane A2 synthesis inhibitor. J Cardiovasc Pharmacol 5:842–847
Burke SE, Lefer AM, Nicolaou KC, Smith GM, Smith JB (1983b) Reponsiveness of platelets and coronary arteries from different species to synthetic thromboxane and prostaglandin endoperoxide analogs. Br J Pharmacol 78:287–292
Bush LR, Campbell WB, Buja LM, Tilton GD, Willerson JT (1984) Effects of the selective thromboxane synthetase inhibitor dazoxiben on variation in cyclic blood flow in stenosed canine coronary arteries. Circulation 69:1161–1170
Butkus A, Skrinska VA, Schumacher OP (1980) Thromboxane production and platelet aggregation in diabetic subjects with clinical complications. Thromb Res 19:211–223
Camussi G, Montrucchio G, Alloatti G, Mariano F, Coda R, Tetta C, Emanuelli G (1984) Platelet-dependent and independent cardiovascular effects of platelet-activating factor (PAF) (Abstr). In: Neri Serneri GG, Masotti G, Gensini GF (eds) Platelets prostaglandins and the cardiovascular system. Boehringer, Ingelheim, Florence, p 160
Capurro N, Levi R (1975) The heart as a target organ in systemic allergic reactions. Comparison of cardiac anaphylaxis in vivo and in vitro. Circ Res 36:520–528
Carter AJ, Bevan JA, Hanley SP, Morgan WE, Turner DR (1984) A comparison of human pulmonary arterial and venous prostacyclin and thromboxane synthesis — effect of a thromboxane synthetase inhibitor. Thromb Haemost 51:257–260
Carvalho ACA, Colman RW, Lees RS (1974) Platelet function in hyperlipoproteinemia. N Engl J Med 290:434–438
Casals-Stenzel J, Buse M, Losert W (1983) Comparison of the vasodepressor action of ZK 36374, a stable prostaglandin derivative, PGI2 and PGE1, with their effect on platelet aggregation and bleeding time in rats. Prostaglandins Leukotrienes Med 10:197–212
Cazenave JP, Benveniste J, Mustard JF (1979) Aggregation of rabbit platelets by platelet-activating factor is independent of the release reaction and the arachidonate pathway and inhibited by membrane active drugs. Lab Invest 41:275–285
Cerletti C, Rajtar G, Bertelé V, de Gaetano G (1984) Inhibition of arachidonate-induced human platelet aggregation by a single low oral dose of aspirin in combination with a thromboxane synthetase inhibitor. Thromb Haemost 52:215
Chakravarty N (1960a) The mechanism of histamine release in anaphylactic reaction in guinea pig and rat. Acta Physiol Scand 48:146–166
Chakravarty N (1960b) The occurrence of a lipid-soluble smooth muscle-stimulating principle (“SRS”) in anaphylactic reaction. Acta Physiol Scand 48:167–177
Chapple DJ, Dusting GJ, Hughes R, Vane JR (1978) A vagal reflex contributes to the hypotensive effect of prostacyclin in anaesthetized dogs. J Physiol (Lond) 281:43P–44P
Chapple DJ, Dusting GJ, Hughes R, Vane JR (1980) Some direct and reflex cardiovascular actions of prostacyclin (PGI2) and prostaglandin E2 in anaesthetized dogs. Br J Pharmacol 68:437–447
Chiabrando C, Castagnoli MN, Noseda A, Fanelli R, Rajtar G, Cerletti C, de Gaetano G (1984) Comparison of radioimmunoassay and high-resolution gas chromatography mass spectrometry for the quantitative determination of serum thromboxane B2 and 6-keto-PGF1α after pharmacological blockade of thromboxane synthetase. Prostaglandins Leukotrienes Med 16:79–88
Chiavarelli M, Moncada S, Mullane KM (1982) Prostacyclin can either increase or decrease heart rate depending on the basal state. Br J Pharmacol 75:243–249
Chien KR, Han A, Sen A, Buja LM, Willerson JT (1984) Accumulation of unesterified arachidonic acid in ischemic canine myocardium. Relationship to a phosphatidylcholine deacylation — reacylation cycle and the depletion of membrane phospholipids. Circ Res 54:313–322
Chierchia S, Patrono C, Crea F, Ciabattoni G, De Caterina R, Cinotti GA, Distante A, Maseri A (1982) Effects of intravenous prostacyclin in variant angina. Circulation 65:470–477
Chignard M, Le Couedic JP, Tence M, Vargaftig BB, Benveniste J (1970) The role of platelet-activating factor in platelet aggregation. Nature 279:799–800
Christ-Hazelhof E, Nugteren DH, Van Dorp DA (1976) Conversion of prostaglandin endoperoxides by glutathione-s-transferases and serum albumins. Biochim Biophys Acta 450:450–461
Christofinis GJ, Moncada S, Bunting S, Vane JR (1979) Prostacyclin release of rabbit aorta and human umbilical vein endothelial cells after prolonged subculture. In: Vane JR, Bergström S (eds) Prostacyclin. Raven, New York, pp 77–84
Coker SJ, Parrat JR, Ledingham I McA, Zeitlin IJ (1981) Early release of thromboxane and 6-keto-PGF1α from the ischemic canine myocardium; relation to early post-infarction arrhythmias. Nature 291:323–324
Colli S, Lombroso M, Maderna P, Tremoli E, Nicosia S (1983) Effects of PGI2 on platelet aggregation and adenylate cyclase activity in human type IIA hypercholesterolemia. Biochem Pharmacol 32:1989–1993
Coombs RRA, Gell PGH (1968) Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Gell PGH, Coombs RRA (eds) Clinical aspects of immunology, 2nd edn. Blackwell, Oxford, pp 575–596
Corey EJ, Niwa N, Falck JR, Mioskowski C, Arai Y, Marfat A (1980) Recent studies on the chemical synthesis of eicosanoids. Adv Prostaglandin Thromboxane Res 6:19–25
Coronary Drug Project Research Group (1976) Aspirin in coronary heart disease. J Chron Dis 29:625–642
Cortellaro M, Boschetti C, Antoniazzi V, Moreo G, Repetto S, Verna E, Boscarini M, Limido A, Binaghi G, Polli EE (1983) Transcoronary platelet thromboxane A2 formation without platelet trapping in patients with coronary stenosis — effect of sulphinpyrazone treatment. Thromb Haemost 50:857–859
Criep LH (1931) Electrocardiographic studies of the effect of anaphylaxis in the cardiac mechanism. Arch Intern Med 48:1098–1109
Criep LH, Woehler TR (1971) The heart in human anaphylaxis. Ann Allergy 29:399–409
Culp BR, Lands WEM, Lucchesi BR, Pitt B, Romson J (1980) The effect of dietary supplementation of fish oil on experimental myocardial infarction. Prostaglandins 20:1021–1030
Dahlén SE, Björk J, Hedqvist P, Arfors KE, Hammarström S, Lindgren JA, Samuelsson B (1981) Leukotrienes promote plasma leakage and leukocyte adhesion in post-capillary venules: In vivo effects with relevance to the acute inflammatory response. Proc Natl Acad Sci USA 78:3887–3891
Dale J, Thaulow E, Myhre E, Parry J (1983) The effect of a thromboxane synthetase inhibitor dazoxiben and acetylsalicylic acid on platelet function and prostaglandin metabolism. Thromb Haemost 50:703–706
D'Angelo V, Villa S, Mysliwiec M, Donati MB, de Gaetano B (1978) Defective fibrinolytic and prostacyclin-like activity in human atheromatous plaques. Thromb Haemost 39:535–536
Darsee JR, Kloner RA, Braunwald E (1981) Demonstration of lateral and epicardial border zone salvage by flurbiprofen using an in vivo method for assessing myocardium at risk. Circulation 63:29–35
Davi G, Custro N, Novo S, Mattina S, Strano A (1983) The effect of two low doses of aspririn on whole blood thromboxane and prostacyclin generation in healthy subjects. Thromb Haemost 50:669–670
Davies RA, Thakur ML, Berger HJ, Wackers PJTH, Gottschalk A, Zaret BL (1981) Imaging the inflammatory response to acute myocardial infarction in man using indium-111-labeled autologous platelets. Circulation 63:826–832
Davis K, Ginsburg R, Bristow M, Harrison DC (1980) Biphasic action of prostacyclin in the human coronary artery. Clin Res 28:3A
Dawson W, Boot JR, Cockerill AF, Mallen DNB, Osborne DJ (1976) Release of novel prostaglandins and thromboxanes after immunological challenge of guinea-pig lung. Nature 262:699–702
De Deckere EAM (1979) Effects of prostaglandins on coronary flow rate and left ventricular work in isolated rat heart. Eur J Pharmacol 58:211–213
De Deckere EAM, Nugteren DH, Ten Hoor F (1977) Prostacyclin is the major prostaglandin released from the isolated perfused rabbit and rat heart. Nature 268:160–163
Dembinska-Kiéc A, Gryglewska T, Zmuda A, Gryglewski RJ (1977) The generation of prostacyclin by arteries and by the coronary vascular bed is reduced in experimental atherosclerosis in rabbits. Prostaglandins 14:1025–1034
Dembinska-Kieć A, Rücker W, Schönhöfer PS (1979) PGI2 enhanced cAMP content in bovine coronary arteries in the presence of isobutylmethylxanthine. Naunyn Schmiedebergs Arch Pharmacol 308:107–110
De Mello VR, Roberts R, Sobel BE (1975) Deleterious effects of methylprednisolone in patients with evolving myocardial infarction. Clin Res 23:179A
Dreyfuss F, Zahavi J (1973) Adenosine diphosphate induced platelet aggregation in myocardial infarction and ischemic heart disease. Atherosclerosis 17:107–120
Dusting GJ, Angus JA (1984) Interaction of epoprostenol (PGI2) with vasoconstrictors on diameter of large coronary arteries of the dog. J Cardiovasc Pharmacol 6:20–27
Dusting GJ, Moncada S, Vane JR (1977a) Prostacyclin is a weak contractor of coronary arteries of the pig. Eur J Pharmacol 45:301–304
Dusting GJ, Moncada S, Vane JR (1977b) Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachidonic acid. Prostaglandins 13:3–15
Dusting GJ, Chapple DJ, Hughes R, Moncada S, Vane JR (1978) Prostacyclin (PGI2) induces coronary vasodilatation in anaesthetized dogs. Cardiovasc Res 12:720–730
Dyerberg J, Bang HO (1979) Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 2:433–435
Dyerberg J, Jørgensen KA (1980) The effect of arachidonic-and eicosapentaenoic acid on the synthesis of prostacyclin-like material in human umbilical vasculature. Artery 8:12–17
Dyerberg J, Bang HO, Hjørne N (1975) Fatty acid composition of the plasma lipids in Greenland Eskimos. Am J Clin Nutr 28:958–966
Dyerberg J, Bang HO, Stoffersen E, Moncada S, Vane JR (1978) Eicosapentaenoic acid and prevention of thrombosis and atherosclerosis. Lancet 2:117–119
Dyerberg J, Jørgensen KA, Arnfred T (1981) Human umbilical blood vessel converts all cis-5,8-11,14,17 eicosapentaenoic acid to prostaglandin I3. Prostaglandins 22:857–862
Editorial (1980) Aspirin after myocardial infarction. Lancet 1:1172–1173
Edlund A, Berglund B, Kaijser L, Patrono C, Sollevi A, van Dorne D, Wennmalm A (1983) Release of adenosine and prostacyclin from ischemic human hearts. Adv Prostaglandin Thromboxane Leukotriene Res 11:365–370
Edmonds LC, Lefer AM (1984) Protective actions of a new thromboxane synthetase inhibitor in arachidonate induced sudden death. Life Sci 35:1763–1768
Egan RW, Paxton J, Kuehl FA Jr (1976) Mechanism of irreversible self-deactivation of prostaglandin synthetase. J Biol Chem 251:7329–7335
Ellis EF, Oelz O, Roberts LJ II, Payne NA, Sweetman BJ, Nies AS, Oates JA (1976) Coronary arterial smooth muscle contraction by a substance released from platelets: Evidence that it is thromboxane A2. Science 193:1135–1137
Elwood PC, Sweetnam PM (1979) Aspirin and secondary mortality after myocardial infarction. Lancet 2:1313–1317
Elwood PC, Cochrane AL, Burr ML, Sweetnam PM, Williams G, Welsby E, Hughes SJ, Renton R (1974) A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J 1:436–440
EPSIM Research Group (1982) A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 307:701–708
Ertl G, Fiedler V, Abram TS, Kochsiek K (1984) Coronary effects of leukotriene C4 and D4 at normal and reduced coronary perfusion (Abstr). 2nd International Symposium on Prostaglandins in the Cardiovascular System, Nürnberg-Fürth, May 9–11
Ezeamuzie IC, Assem ESK (1983) Effects of leukotrienes C4 and D4 on guinea-pig heart and the participation of SRS-A in the manifestation of guinea-pig cardiac anaphylaxis. Agents Actions 13:182–187
Feigen GA, Prager DJ (1969) Experimental cardiac anaphylaxis. Physiologic, pharmacologic and biochemical aspects of immune reactions in the isolated heart. Am J Cardiol 24:474–491
Feigen GA, Vaughan Williams EM, Peterson JK, Nielsen CB (1960) Histamine release and intracellular potentials during anaphylaxis in the isolated heart. Circ Res 8:713–723
Feldberg W, Kellaway CH (1938) Liberation of histamine and formation of lysocithinlike substances by cobra venom. J Physiol (Lond) 94:187–226
Ferreira SH, Moncada S, Vane JR (1971) Indomethacin and aspirin abolish prostaglandin release from the spleen Nature (New Biol) 231:237–239
Fésüs L, Csaba B, Muszbek L (1977) Platelet-activating factor, the trigger of hemostatic alterations in rat anaphylaxis. Clin Exp Immunol 27:512–515
Feuerstein G, Ezra D, Hayes E, Ramwell PW, Goldstein RE (1984a) Effects of platelet activating factor on coronary circulation, cardiac function and coronary vein level of 6-keto-PGF1α , TXB2 and leukotriene C4-like immunoreactivity of the intact domestic pig heart (Abstr). In: Neri Serneri GG, Masotti G, Gensini GF (eds) Platelets prostaglandins and the cardiovascular system. Boehringer-Ingelheim, Florence, p 159
Feuerstein G, Boyd LM, Ezra D, Goldstein RE (1984b) Effect of platelet-activating factor on coronary circulation of the domestic pig. Am J Physiol 246:466–471
Feuerstein N, Ramwell PW (1981) OKY-1581, a potential selective thromboxane synthetase inhibitor. Eur J Pharmacol 69:533–534
Fiedler VB (1983) Reduction of myocardial infarction and dysrhythmic activity by nafazatrom in the conscious rat. Eur J Pharmacol 88:263–267
Fiedler VB (1984) Reduction of acute myocardial ischemia in rabbit hearts by nafazatrom. J Cardiovasc Pharmacol 6:318–324
Fiedler VB, Mardin M, Abram TS (1984) Nifedipine on cardiovascular leukotriene D4 actions in the anaesthetized dog. Eur J Pharmacol 104:159–164
Fischer S, Weber PC (1983) Thromboxane A3 (TXA3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5ω3). Biochem Biophys Res Commun 116:1091–1099
Fischer S, Weber PC (1984) Prostaglandin I3 is formed in vivo in man after dietary eicosapentaenoic acid. Nature 307:165–168
Fischer S, Struppler M, Böhlig B, Bernutz C, Weber W, Weber PC (1983) The influence of selective thromboxane synthetase inhibition with a novel imidazole derivative, UK-38 485, on prostanoid formation in man. Circulation 68:821–826
Fishbein MC, Maclean D, Maroko PR (1978) The histopathologic evaluation of myocardial infarction. Chest 73:843–849
FitzGerald DJ, Roy L, Robertson RM, FitzGerald GA (1984) The effect of organic nitrates on prostacyclin biosynthesis and platelet function in humans. Circulation 70:297–302
FitzGerald GA, Oates JA (1984) Selective and nonselective inhibition of thromboxane formation. Clin Pharmacol Ther 35:633–640
FitzGerald GA, Sherry S (1982) Pharmacology and pharmacokinetics of plateletactive drugs under current clinical investigation. In: Oates JA (ed) Prostaglandins and the cardiovascular system. Raven, New York, pp 107–172
FitzGerald GA, Friedman LA, Miyamori I, Grady JO, Lewis PJ (1979) A double blind placebo controlled crossover study of prostacyclin in man. Life Sci 25:665–672
FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts LJ, Lawson JA, Brash AR (1983a) Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 71:676–688
FitzGerald GA, Pedersen AK, Patrono C (1983b) Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 67:1174–1177
FitzGerald GA, Smith B, Pedersen AK, Brash AR (1984) Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 310:1065–1068
Fitzpatrick FA, Gorman RR (1978) A comparison of imidazole and 9,11-azoprosta-5,13-dienoic acid; two selective thromboxane synthetase inhibitors. Biochim Biophys Acta 539:162–173
Flower RJ (1974) Drugs which inhibit prostaglandin biosynthesis. Phrarmacol Rev 26:33–67
Flower RJ, Blackwell GJ (1976) The importance of phospholipase A2 in prostaglandin biosynthesis. Biochem Pharmacol 25:285–291
Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJH (1980) Leukotriene B, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes. Nature 286:264–265
Foster RF, Layman JD (1952) Generalized urticaria with electrocardiographic changes simulating myocardial infarction. JAMA 148:203–205
Friedman PL, Brown EJ, Gunther S, Alexander RW, Barry WH, Mudge GH Jr, Grossman W (1981) Coronary vasoconstrictor effect of indomethacin in patients with coronary-artery disease. N Engl J Med 305:1171–1175
Ganz P, Gaspar J, Colucci WS, Barry WH, Mudge GH, Alexander RW (1984) Effects of prostacyclin on coronary hemodynamics at rest and in response to cold pressor testing in patients with angina pectoris. Am J Cardiol 53:1500–1504
Gerrard JM, Stuart MJ, Rao GHR, Steffes MW, Mauer SM, Brown DM, White JG (1980) Alteration in the balance of prostaglandin and thromboxane synthesis in diabetic rats. J Lab Clin Med 95:950–958
Ginsburg R, Bristow MR, Harrison DC, Stinson EB (1980) Studies with isolated human coronary arteries. Some general observations, potential mediators of spasm, role of calcium antagonists. Chest 78:180–186
Giotti A, Guidotti A, Mannaioni PF, Zilletti L (1966) The influence of adrenotropic drugs and noradrenaline on the histamine release in cardiac anaphylaxis in vitro. J Physiol (Lond) 184:924–941
Goetzl EJ, Pickett WC (1980) The human PMN leukocyte chemotactic activity of complex hydroxyeicosatetraenoic acids (HETEs). J Immunol 125:1789–1791
Goldblatt MW (1935) Properties of human seminal plasma. J Physiol (Lond) 84:208–218
Gorman RR, Bunting S, Miller OV (1977a) Modulation of human platelet adenylate cyclase by prostacyclin (PGX). Prostaglandins 13:377–388
Gorman RR, Fitzpatrick FA, Miller OV (1977b) A selective thromboxane synthetase inhibitor blocks the cAMP lowering activity of PGH2. Biochem Biophys Res Commun 79:305–313
Gorman RR, Johnson RA, Spilman CH, Aiken JW (1983) Inhibition of platelet thromboxane A2 synthase activity by sodium 5-(3′-pyridinyl methyl)benzofuran-2-carboxylate. Prostaglandins 26:325–342
Green LH, Seroppian E, Handin RI (1980) Platelet activation during exercise-induced myocardial ischemia. N Engl J Med 302:193–197
Greenwald JE, Bianchine JR, Wong LK (1979) The production of the arachidonate metabolite HETE in vascular tissue. Nature 281:588–589
Gryglewski RJ (1976) Steroid hormones, anti-inflammatory steroids and prostaglandins. Pharmacol Res Commun 8:337–348
Gryglewski R, Vane JR (1972) The release of prostaglandins and rabbit aorta contracting substance (RCS) from rabbit spleen and its antagonism by anti-inflammatory drugs. Br J Pharmacol 45:37–47
Gryglewski RJ, Bunting S, Moncada S, Flower RJ, Vane JR (1976) Arterial walls are protected against deposition of platelet thrombi by a substance (Prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins 12:685–713
Gryglewski RJ, Korbut R, Ocetkiewicz A (1978) Generation of prostacyclin by lungs in vivo and its release into the arterial circulation. Nature 273:765–767
Gryglewski RJ, Salmon JA, Ubatuba FB, Weatherly BC, Moncada S, Vane JR (1979) Effects of all cis-5,8,11,14,17 eicosapentaenoic acid and PGH3 on platelet aggregation. Prostaglandins 18:453–478
Guyton JR, Willerson JT (1977) Peripheral venous platelet aggregates in patients with unstable angina pectoris and acute myocardial infarction. Angiology 28:695–701
Hahn F, Bernauer W (1970) Studies on heart anaphylaxis. III. Effect of antigen and histamine on perfused guinea-pig heart. Arch Int Pharmacodyn 184:129–157
Halushka PV, Rogers RC, Loadholt CB, Colwell JA (1981) Increased platelet thromboxane synthesis in diabetes mellitus. J Lab Clin Med 97:87–96
Hamazaki T, Hirai A, Terano T, Sajiki J, Kondo S, Fujita T, Tamura Y, Kumagai A (1982) Effects of orally administered ethyl ester of eicosapentaenoic acid (EPA; C20:5, ω-3) on PGI2-like substance production by rat aorta. Prostaglandins 23:557–567
Hamberg M (1976) On the formation of thromboxane B2 and 12-hydroxy-5,8,10,14-eicosatetraenoic acid (12ho-20:4) in tissues from the guinea pig. Biochim Biophys Acta 431:651–654
Hamberg M, Fredholm BB (1976) Isomerization of prostaglandin H2 into prostaglandin D2 in the presence of serum albumin. Biochim Biophys Acta 431:189–193
Hamberg M, Samuelsson B (1974) Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc Natl Acad Sci USA 71:3400–3404
Hamberg M, Svensson J, Samuelsson B (1974a) Prostaglandin endoperoxides. A new concept concerning the mode of action and release of prostaglandins. Proc Natl Acad Sci USA 71:3824–3828
Hamberg M, Svensson J, Wakabayashi T, Samuelsson B (1974b) Isolation and structure of two prostaglandin endoperoxides that cause platelet aggregation. Proc Natl Acad Sci USA 71:345–349
Hamberg M, Svensson J, Samuelsson B (1975) Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci USA 72:2994–2998
Hammarström S (1983) Leukotrienes. Annu Rev Biochem 52:355–377
Hammarström S, Falardeau P (1977) Resolution of prostaglandin endoperoxide synthase and thromboxase synthase of human platelets. Proc Natl Acad Sci USA 74:3691–3695
Hammarström S, Murphy RC, Samuelsson B, Clark DA, Mioskowski C, Corey EJ (1979) Structure of leukotriene C. Identification of the amino acid part. Biochem Biophys Res Commun 91:1266–1272
Hanashiro PK, Weil MH (1967) Anaphylactic shock in man. Report of two cases with detailed hemodynamic and metabolic studies. Arch Intern Med 119:129–140
Harrison HE, Reece AH, Johnson M (1978) Decreased vascular prostacyclin in experimental diabetes. Life Sci 23:351–356
Hartmann JR, Robinson JA, Gunnar RM (1977) Chemotactic activity in the coronary sinus after experimental myocardial infarction: Effects of pharmacologic interventions on ischemic injury. Am J Cardiol 40:550–555
Hassam AG, Crawford MA (1976) The differential incorporation of labelled linoleic, γ-linolenic, dihomo-γ-linolenic and arachidonic acids into the developing rat brain. J Neurochem 27:967–968
Hattori Y, Levi R (1984) Negative inotropic effect of leukotrienes: leukotriene C4 and D4 inhibit calcium-dependent contractile responses in potassium-depolarized guinea-pig myocardium. J Pharmacol Exp Ther 230:646–651
Heffner JE, Shoemaker SA, Canham EM, Patel M, McMurtry IF, Morris HG, Repine JE (1983) Acethyl glyceryl ether phosphorylcholine-stimulated human platelets cause pulmonary hypertension and edema in isolated rabbit lungs. J Clin Invest 71:351–357
Hemler M, Lands WEM, Smith WL (1976) Purification of the cyclooxygenase that forms prostaglandins. Demonstration of two forms of iron in the holoenzyme. J Biol Chem 251:5575–5579
Herbaczynska-Cedro K, Moncada S, Mullane KM, Vane JR (1982) Effects of thromboxane A2 on the coronary circulation in vivo (Abstr). 5th International Conference on Prostaglandins, Florence, May 18–21, p 277
Herman AG, Claeys M, Moncada S, Vane JR (1979) Biosynthesis of prostacyclin (PGI2) and 12L-hydroxy-5,8,10,14 eicosatetraenoic acid (HETE) by pericardium, pleura, peritoneum and aorta of the rabbit. Prostaglandins 18:439–452
Higgs GA, Vane JR (1983) Inhibition of cyclooxygenase and lipoxygenase. Br Med Bull 39:265–270
Higgs GA, Bunting S, Moncada S, Vane JR (1976) Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. Prostaglandins 12:749–757
Higgs GA, Moncada S, Vane JR (1977) Prostacyclin (PGI2) inhibits the formation of platelet thrombi induced by adenosine diphosphate (ADP) in vivo. Br J Pharmacol 61:137P
Higgs GA, Flower RJ, Vane JR (1979) A new approach to anti-inflammatory drugs. Biochem Pharmacol 28:1959–1961
Higgs GA, Eakins KE, Mugridge KG, Moncada S, Vane JR (1980) The effects of nonsteroid anti-inflammatory drugs on leukocyte migration in carrageenin-induced inflammation. Eur J Pharmacol 66:81–86
Higgs GA, Mugridge KG, Moncada S, Vane JR (1984) Inhibition of tissue damage by the arachidonate lipoxygenase inhibitor BW755C. Proc Natl Acad Sci USA 81:2890–2892
Hill JH, Ward PA (1971) The phlogistic role of C3 leukotactic fragments in myocardial infarcts of rats. J Exp Med 133:885–900
Hillis LD, Braunwald E (1977) Myocardial ischemia. N Engl J Med 296:971–978
Hillis LD, Braunwald E (1978) Coronary-artery spasm. N Engl J Med 299:695–702
Hintze TH, Kaley G (1984) Ventricular receptors activated following myocardial prostaglandin synthesis initiate reflex hypotension, reduction in heart rate, and redistribution of cardiac output in the dog. Circ Res 54:239–247
Hintze T, Kaley G, Martin EG, Messina EJ (1978) PGI2 induces bradycardia in the dog. Prostaglandins 15:712
Hintze TH, Martin EG, Messina EJ, Kaley G (1979) Prostacyclin (PGI2) elicits reflex bradycardia in dogs: evidence for vagal mediation. Proc Soc Exp Biol Med 162:96–100
Hintze TH, Panzenbeck MJ, Messina EJ, Kaley G (1981) Prostacyclin (PGI2) lowers heart rate in the conscious dog. Cardiovasc Res 15:538–546
Hintze TH, Kichuk MR, Stern H, Harrison J, Kaley G (1984) Prostacyclin dilates large coronary arteries in conscious dogs (Abstr). In: Neri Serneri GG, Masotti G, Gensini GF (eds) Platelets prostaglandins and the cardiovascular system. Florence, p 96
Hirata F, Schiffmann E, Venkatasubramanian K, Salomon D, Axelrod J (1980) A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci USA 77:2533–2536
Hirsh SA (1982) Acute allergic reaction with coronary vasospasm. Am Heart J 103:928
Hirsh PD, Hillis LD, Campbell WB, Firth BG, Willerson JT (1981) Release of prostaglandins and thromboxane into the coronary circulation in patients with ischemic heart disease. N Engl J Med 304:685–691
Hirsh PD, Firth BG, Campbell WB, Willerson JT, Hillis LD (1982) Influence of blood sampling site and technique on thromboxane concentrations in patients with ischemic heart disease. Am Heart J 104:234–237
Hong SCL, Levine L (1976) Inhibition of arachidonic acid release from cells as the biochemical action of anti-inflammatory corticoids. Proc Natl Acad Sci USA 73:1730–1734
Hornstra G, Christ-Hazelhof E, Haddeman E, ten Hoor F, Nugteren DH (1981) Fish oil feeding lowers thromboxane and prostacyclin production by rat platelets and aorta and does not result in the formation of prostaglandin I3. Prostaglandins 21:727–738
Hsueh W, Needleman P (1978) Sites of lipase activation and prostaglandin synthesis in isolated, perfused rabbit hearts and hydronephrotic kidneys. Prostaglandins 16:661–681
Imai S, Takeda K, Nakagawa Y, Nakazawa M, Shimamoto N, Katano Y (1983) Effects of prostaglandins and related compounds on the canine coronary artery and arteriole. Adv Prostaglandin Thromboxane Leukotriene Res 11:401–405
Ingerman-Wojenski C, Silver MJ, Smith JB, Macarak E (1981) Bovine endothelial cells in culture procedure thromboxane as well as prostacyclin. J Clin Invest 67:1292–1296
Irvine RF (1982) How is the level of free arachidonic acid controlled in mammalian cells? Biochem J 204:3–16
Isakson PC, Raz A, Denny SE, Wyche A, Needleman P (1977) Hormonal stimulation of arachidonate release from isolated perfused organs. Relationship to prostaglandin biosynthesis. Prostaglandins 14:853–871
Ito T, Ogawa K, Enomoto I, Hashimoto H, Kai I, Satake T (1980) Cormparison of the effects of PGI2 and PGE1 on coronary and systemic hemodynamics and coronary arterial cyclic nucleotide levels in dogs. Adv Prostaglandin Thromboxane Res 7:641–646
Jakubowski JA, Ardlie NG (1979) Evidence for the mechanism by which eicosapentaenoic acid inhibits human platelet aggregation and secretion-implications for the prevention of vascular disease. Thromb Res 16:205–217
Johnson AS, Scheinberg SR, Gerisch RA, Saltzstein HC (1953) Effect of cortisone on the size of experimentally produced infarcts. Circulation 7:224–228
Johnson RA, Morton DR, Kinner JH, Gorman RR, McGuire JC, Sun FF, Wittacker N, Bunting S, Salmon J, Moncada S, Vane JR (1976) The chemical structure of prostaglandin X (prostacyclin). Prostaglandins 12:915–928
Jørgensen KA, Steffersen E, Dyerberg J (1979) Stability of prostacyclin in plasma. Lancet 1:1352
Jouve R, Rolland PH, Delboy C, Mercier C (1984) Thromboxane B2, 6-keto-PGF1α, PGE2, PGF2α and PGA1 plasma levels in arteriosclerosis obliterans: Relationship to clinical manifestation, risk factors, and arterial pathoanatomy. Am Heart J 107:45–52
Jugdutt BI, Hutchins GM, Bulkley BH, Pitt B, Becker LC (1979) Effect of indomethacin on collateral blood flow and infarct size in the conscious dog. Circulation 4:734–743
Jugdutt BI, Hutchins GM, Bulkley BH, Becker LC (1980) Salvage of ischemic myocardium by ibuprofen during infarction in the conscious dog. Am J Cardiol 46:74–82
Jugdutt BI, Hutchins GM, Bulkley GH, Becker LC (1981) Dissimilar effects of prostacyclin, prostaglandin E1 and prostaglandin E2 on myocardial infarct size after coronary occlusion in conscious dogs. Circ Res 49:685–700
Kaley G, Hintze TH, Messina EJ (1980) Role of prostaglandins in ventricular reflexes. Adv Prostaglandin Thromboxane Res 7:601–608
Karim SMM, Sandler M, Williams ED (1967) Distribution of prostaglandins in human tissues. Br J Pharmacol Chemother 31:340–344
Karim SMM, Hillier K, Devlin J (1968) Distribution of prostaglandins E1, E2, F1α and F2α in some animal tissues. J Pharm Pharmacol 20:749–753
Karmazyn M (1983) Reduction of enzyme release from perfused ischemic hearts by steroidal and non-steroidal prostaglandin synthesis inhibitors. Prostaglandins Leukotrienes Med 11:299–315
Karmazyn M, Horrobin DF, Manku MS, Cunnane SC, Karmali RA, Ally AI, Morgan RO, Nicolaou KC, Barnette WE (1978) Effects of prostacyclin on perfusion pressure, electrical activity, rate and force of contraction in isolated rat and rabbit hearts. Life Sci 22:2079–2086
Kellaway CH, Trethewie ER (1940) The liberation of a slow-reacting smooth-muscle stimulating substance in anaphylaxis. Q J Exp Physiol 30:121–145
Kelly JF, Patterson P (1974) Anaphylaxis. Course, mechanism, and streatment. JAMA 227:1431–1436
Kirmser R, Berger HJ, Cohen LS, Wolfson S (1976) Effect of indomethacin, a prostaglandin inhibitor on epicardial ST elevation and myocardial flow after coronary occlusion. Circulation (Suppl 2) 53/54:II-194
Klitzke AK (1984) Nafazatrom (BAYg6575), a potent stimulator of prostacyclin release from cardiac and renal vessel wall. Arch Int Pharmacodyn 271:220–228
Klitzke AK, Trompler AT (1984) Leukotriene C4 stimulates prostacyclin release from the cardiac vessel wall (Abstr). In: Neri Serneri GG, Mastotti G, Gensini GF (eds) Platelets prostaglandins and the cardiovascular system. Bohringer-Ingelheim, Florence, p 43
Kloner RA, Fishbein MC, Lew H, Maroko PR, Braunwald E (1978) Mummification of the infarcted myocardium by high dose corticosteroids. Circulation 57:56–63
Körner CF, Hausmann G, Gemsa D, Resch K (1984) Rate of prostaglandin synthesis is not controlled by phospholipase A activity but reincorporation of released fatty acids into phospholipids. Agents Actions 15:28–30
Korth R, Riess H, Brehm G, Hiller E (1984) Influence of unsaturated platelet-activating factor on aggregation, serotonin release and thomboxane synthesis of human thrombocytes (Abst). In: Neri Serneri GG, Masotti G, Gensini GF (eds) Platelets prostaglandins and the cardiovascular system. Boehringer-Ingelheim, Florence, p 157
Kraemer RJ, Phernetton TM, Folts JD (1976) Prostaglandin-like substances in coronary venous blood following myocardial ischemia. J Pharmacol Exp Ther 199:611–619
Krell RD, Osborn R, Falcone K, Vickery L (1981) Enhancement of isolated airway response to bronchoconstrictive agonists by the slow-reacting substance of anaphylaxis FPL 55712. Prostaglandins 22:423–432
Kröner EE, Peskar BA, Fischer H, Ferber E (1981) Control of arachidonic acid accumulation in bone marrow-derived macrophages by acetyltransferases. J Biol Chem 256:3690–3697
Ku EC, McPherson SE, Signor C, Chertock H, Cash WD (1983) Characterization of imidazo(1,5-a)pyridine-5-hexanoic acid (CGS-13080) as a selective thromboxane synthetase inhibitor using in vitro and in vivo biochemical models. Biochem Biophys Res Commun 112:899–906
Kukovetz WR, Holzmann S, Wurm A, Pöch G (1979) Prostacyclin increase cAMP in coronary arteries. J Cyclic Nucleotide Res 5:469–475
Kulmacz RJ, Lands WEM (1983) Characteristics of prostaglandin H synthetase. Adv Prostaglandin Thromboxane Leukotriene Res 11:93–97
Kunze H, Vogt W (1971) Significance of phospholipase A for prostaglandin formation. Ann NY Acad Sci 180:123–125
Kurzrock R, Lieb CC (1930) Biochemical studies of human semen. II. The action of semen on the human uterus. Proc Soc Exp Biol Med 28:268–272
Lands WEM (1979) The biosynthesis and metabolism of prostaglandins. Annu Rev Physiol 41:633–652
Lands WEM, Samuelsson B (1968) Phospholipid precursors of prostaglandins. Biochim Biophys Acta 164:426–429
Larrue J, Leroux C, Daret D, Bricaud H (1982) Decreased prostaglandin production in cultured smooth muscle cells from atherosclerotic rabbit aorta. Biochim Biophys Acta 710:257–263
Lee T, Malone B, Blank ML, Snyder F (1981) 1-alkyl-2-acethyl-sn-glycero-3-phosphocholine (platelet-activating factor) stimulates calcium influx in rabbit platelets. Biochem Biophys Res Commun 102:1262–1268
Lefer AM, Polansky EW (1979) Beneficial effects of ibuprofen in acute myocardial ischemia. Cardiology 64:265–274
Lefer AM, Ogletree ML, Smith JB, Silver MJ, Nicolaou KC, Barnette WE, Gasic GP (1978) Prostacyclin: A potentially valuable agent for preserving myocardial tissue in acute myocardial ischemia. Science 200:52–54
Lefer AM, Okamatsu S, Smith EF III, Smith JB (1981) Beneficial effect of a new thromboxane synthetase inhibitor in arachidonate-induced sudden death. Thromb Res 23:265–273
Lefer AM, Müller HF, Smith JB (1984) Pathophysiological mechanisms of sudden death induced by platelet activating factor. Br J Pharmacol 83:125–130
Letts LG, Piper JP (1981) The effects of leukotrienes (LT) D4 and C4 on the guineapig isolated heart. J Physiol (Lond) 317:94P–95P
Letts LG, Piper PJ (1982) The actions of leukotrienes (LT) C4 and D4 on the guineapig isolated heart. Br J Pharmacol 76:169–176
Letts LG, Piper PJ (1983) Cardiac actions of leukotrienes B4, C4, D4 and E4 in guinea pig and rat in vitro. Adv Prostaglandin Thromboxane Leukotriene Res 11:391–395
Letts LG, Newman DL, Greenwald SE, Piper PJ (1983a) Effects of intra-coronary administration of leukotriene D4 in the anaesthetized dog. Prostaglandins 26:563–572
Letts LG, Piper PJ, Newman DL (1983b) Leukotrienes and their action on the coronary circulation. In: Piper PJ (ed) Leuktorienes and other lipoxygenase products. Research Studies Press, Chichester, pp 94–107
Levi R (1972) Effects of exogenous and immunologically released histamine on the isolated heart: a quantitative comparison. J Pharmacol Exp Ther 182:227–238
Levi R, Burke JA (1980) Cardiac anaphylaxis: SRS-A potentiates and extends the effects of released histamine. Eur J Pharmacol 62:41–49
Levi R, Allan G, Zavecz JH (1976) Prostaglandins and cardiac anaphylaxis. Life Sci 18:1255–1264
Levi R, Burke JA, Holland BA (1979) Slow reacting substance of anaphylaxis (SRS-A): Possible role in cardiac hypersensitivity reactions. Fed Proc 38:261
Levi R, Burke JA, Corey EJ (1982) SRS-A, leuktrienes, and immediate hypersensitivity reactions of the heart. In: Samuelsson, B., Paoletti R (eds) Leukotrienes and other lipxoygenase products. Raven, New York, pp 215–222
Levi R, Burke JA, Guo ZG, Hattori Y, Hoppens CM, McManus LM, McManus LM, Hanahan DJ, Pinckard RN (1984) Acetyl glcyerly ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig. Circ Res 54:117–124
Levine PH (1973) On acute effect of cigarette smoking on platelet function. Circulation 48:619–623
Levy JV (1978) Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue. Prostaglandins 16:93–97
Lewis HD, Davis JW, Archibal DG, Steinke WE, Smitherman TC, Doherty JE, Schnaper HW, Le Winter MM, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H (1983) Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 309:396–403
Lewis RA, Drazen JM, Austen KF, Clark DA, Corey EJ (1980a) Identification of the C(6)-S-conjugate of leukotriene A with cysteine as a naturally occurring slow reacting substance of anaphylaxis (SRS-A). Importance of the 11-cis-geometry for biological activity. Biochem Biophys Res Commun 96:271–277
Lewis RA, Austen KF, Drazen MJ, Clark DA, Marfat A, Corey EJ (1980b) Slow reacting substances of anaphylaxis: Identification of leukotrienes C-1 and D from human and rat sources. Proc Natl Acad Sci USA 77:3710–3714
Lewy RI, Smith JB, Silver MJ, Saia J, Walinsky P, Wiener L (1979a) Detection of thromboxane B2 in peripheral blood of patients with Prinzmetal's angina. Prostaglandin Med 5:243–248
Lewy RI, Wiener L, Smith JB, Walinsky P, Silver MJ, Saia J (1979b) Comparison of plasma concentrations of thromboxane B2 in Prinzmetal's variant angina and classical angina pertoris. Clin Cardiol 2:404–406
Lewy RI, Wiener L, Walinsky P, Lefer AM, Silver MJ, Smith JB (1980) Thromboxane release during pacing-induced angina pectoris: possible vasoconstrictor influence on the coronary vasculature. Circulation 61:1165–1171
Libby P, Maroko PR, Bloor CM, Sobel BE, Braunwald E (1973) Reduction of experimental myocardial infarct size by corticosteroid administration. J Clin Invest 52:599–607
Leiebig R, Bernauer W, Peskar BA (1975) Prostaglandin, slow-reacting substance, and histamine release from anaphylactic guinea pig hearts, and its pharmacological modification. Naunyn Schmiedebergs Arch Pharmacol 289:65–76
Lilienfeld A, Hochstein E, Weiss W (1950) Acute myocarditis with bundle branch block due to sulfonamide sensitivity. Circulation 1:1060–1064
Lotner GZ, Lynch JM, Betz SJ, Henson PM (1980) Human neutrophil derived plateletactivating factor. J Immunol 124:676–684
Lucchesi BR, Jolly SR, Bailie MB, Abrams GD (1982) Protection of ischemic myocardium by BW755C. Fed Proc 41:8576
Luchi RJ, Chahine RA (1981) Coronary artery spasm, coronary artery thrombosis and myocardial infarction. Ann Intern Med 95:502–505
MacIntyre DE, Pearson JD, Gordon JL (1978) Localization and stimulation of prostacyclin production in vascular cells. Nature 271:549–551
MacIntyre DE, Shaw AM, Pollock WK, Marks G, Westwick J (1982) The role of endogenous arachidonate metabolites in phospholipid-induced human platelet activation (Abstr). 5th International Conference on Prostaglandins, Florence, May 18–21, p 714
Maclean D, Fishbein MC, Braunwald E (1978a) Long-term preservation of ischemic myocardium after experimental coronary artery occlusion. J Clin Invest 61:541–551
Maclean D, Fishbein MC, Blum RI, Braunwald E, Maroko PR (1978b) Long-term preservation of ischemic myocardium by ibuprofen after experimental coronary artery occlusion. Am J Cardiol 41:394
MacNab MW, foltz EL, Graves BS, Rinehart RK, Tripp SL, Feliciano NR, Sen S (1984) The effects of a new thromboxane synthetase inhibitor, CGS-13080, in man. J Clin Pharmacol 24:76–83
Mallory GK, White PD, Salcedo-Salgar J (1939) The speed of healing of myocardial infarction. A study of the pathologic anatomy in seventy-two cases. Am Heart J 18:647–671
Marooka S, Kobayashi M, Shimamoto T (1977) Experimental ischemic heart disease induced by thromboxane A2 in rabbits. Jpn Circ J 41:1373–1379
Maseri A, L'Abbate A, Chierchia S, Parodi O, Severi S, Biagini A, Distante A, Marzilli M, Ballestra AM (1979) Significance of spasm in the pathogenesis of ischemic heart disease. Am J Cardiol 44:788–792
McManus JF, Lawlor JJ (1950) Myocardial infarction following the administration of tetanus antitoxin. N Engl J Med 242:17–19
McManus LM, Hanahan DJ, Demopoulos CA, Pinckard RN (1980) Pathobiology of the intravenous infusion of acetyl glyceryl ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol 124:2919–2924
McManus LM, Hanahan DJ, Pinckard RN (1981) Human platelet stimulation by acetyl glyceryl ether phosphoylacholine. J Clin Invest 67:903–906
McManus LM, Fitzpatrick FA, Hanahan DJ, Pinckard RN (1983) Thromboxane B2 release following acetyl glyceryl ether phosphorylcholine infusion in the rabbit. Immunopharmacology 5:197–207
Meacock SCR, Kitchen EA (1976) Some effects of non-steroidal anti-inflammatory drugs on leukocyte migration. Agents Actions 6:320–325
Metha J, Mehta P, Burger C, Pepine JC (1978) Platelet aggregation studies in coronary artery disease. Part 4. Effect of aspirin. Atherosclerosis 31:169–175
Mehta J, Mehta P, Conti CR (1980a) Platelet function studies in coronary heart disease. IX. Increased platelet prostaglandin generation and abnormal platelet sensitivity to prostacyclin and endoperoxide analog in angina pectoris. Am J Cardiol 46:943–947
Mehta J, Mehta P, Pepine CJ, Conti CR (1980b) Platelet function studies in coronary artery disease. VII. Effect of aspirin and tachycardia stress on aortic and coronary venous blood. Am J Cardiol 45:945–951
Mehta J, Mehta P, Zipper R, Horalek C (1981a) Thromboxane/prostacyclin equilibrium at rest and during exercise in man and its relationship to myocardial ischemia. Clin Res 29:223A
Mehta J, Nichols WW, Mehta P, Pepine C, Conti CR (1981b) Effects of prostacyclin on systemic and coronary hemodynamics in the dog. Am Heart J 102:835–840
Mehta J, Mehta P, Feldman RL (1982) Severe intracoronary thromboxane release preceding acute coronary artery occlusion. Prostaglandins Leukotrienes Med 8:599–605
Mehta J, Mehta P, Feldman RL, Hovalek C (1984a) Thromboxane release in coronary artery disease: spontaneous versus pacing-induced angina. Am Heart J 107:286–292
Mehta J, Nichols WW, Goldman R (1984b) Prostacyclin release following endoperoxide analogue infusion in the intact dog. Am J Physiol 246:R205–R210
Mencia-Huerta JM, Benveniste J (1979) Platelet-activating factor and macrophages. I. Evidence for the release from rat and mouse peritoneal macrophages and not from mastocytes. Eur J Immunol 9:409–415
Mencia-Huerta JM, Ninio E, Landes A, Godfroid JJ, Benveniste J (1981) Enzymatic assembly of platelet-activating factor (PAF-acether). Fed Proc 40:1015
Menys VC, Davies JA (1983) Selective inhibition of thromboxane synthetase with dazoxiben — basis of its inhibitory effect on platelet adhesion. Thromb Haemost 49:96–101
Michelassi F, Landa L, Hill RD, Lowenstein E, Watkins WD, Petkau AJ, Zapol WM (1982) Leukotriene D4: A potent coronary artery vasoconstrictor associated with impaired ventricular contraction. Science 217:841–843
Michelassi F, Landa L, Hill RD, Huttemeier P, Lowenstein E, Zapol WM, Watkins WD (1983) Leukotriene D4: A potent sheep coronary vasoconstrictor not blocked by ibuprofen. Adv Prostaglandin Thromboxane Leukotriene Res 11:397–399
Miyamoto T, Ogino N, Yamamoto S, Hayaishi O (1976) Purification of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 251:2629–2636
Moncada S (1982) Biological importance of prostacyclin. Br J Pharmacol 76:3–31
Moncada S, Vane JR (1978) Unstable metabolites of arachidonic acid and their role in haemostasis and thrombosis. Br Med Bull 34:129–135
Moncada S, Vane JR (1979) Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev 30:293–333
Moncada S, Gryglewski R, Bunting S, Vane JR (1976a) An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 263:663–665
Moncada S, Gryglewski RJ, Bunting S, Vane JR (1976b) A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins 12:715–737
Moncada S, Bunting S, Mullane K, Thorogood P, Vane JR, Raz A, Needleman P (1977a) Imidazole: A selective inhibitor of thromboxane synthetase. Prostaglandins 13:611–618
Moncada S, Herman AG, Higgs EA, Vane JR (1977b) Differential formation of prostacyclin (PGX or PGI2) by layers of the arterial wall. An explanation for the anti-thrombotic properties of vascular endothelium. Thromb Res 11:323–344
Morley J, Bray MA, Jones RW, Nugteren DH, van Dorp DA (1979) Prostaglandin and thromboxane production by human and guinea-pig macrophages and leukocytes. Prostaglandins 17:729–736
Morris HR, Taylor GW, Piper PJ, Tippins JR (1980) Structure of slow-reacting substance of anaphylaxis from guinea pig lung. Nature 285:104–106
Mullane KM, Moncada S (1982) The salvage of ischemic myocardium by BW755C in anaesthetized dogs. Prostaglandins 24:255–266
Mullane KM, Bradley G, Moncada S (1982) The interaction of platelet derived mediators on isolated canine coronary arteries. Eur J Pharmacol 84:115–118
Mullane KM, Read N, Salmon JA, Moncada S (1984) Role of leukocytes in acute myocardial infarction in anaesthetized dogs: Relationship to myocardial salvage by anti-inflammatory drugs. J Pharmacol Exp Ther 228:510–522
Müller B, Schneider J, Hennies HH, Flohé L (1984) Cardioprotective action of the new stable epoprostenol analogue CG 4203 in rat models of cardiac hypoxia and ischemia. Drug Res 34:1506–1509
Murphy RC, Hammarström S, Samuelsson B (1979) Leukotriene C: a slow reacting substance from murine mastocytoma cells. Proc Natl Acad Sci USA 76:4275–4279
Mustard JF, Kinlough-Rathbone RL, Packham MA (1983) Aspirin in the treatment of cardiovascular disease: A Review. Am J Med 74:43–49
Nadler JL, Yamamoto J, Zipser R, Horton R (1984) Nicotine inhibits prostacyclin and stimulates thromboxane in chronic smokers (Abstr). Kyoto Conference on Prostaglandins, Kyoto, November 25–28, p 231
Naito J, Komatsu H, Ujiie A, Hamano S, Kubota T, Tsuboshima M (1983) Effects of thromboxane synthetase inhibitors on aggregation of rabbit platelets. Eur J Pharmacol 91:41–48
Narumiya S, Salmon JA, Cottee FH, Weartherley BC, Flower RJ (1981) Arachidonic acid 15-lipoxygenase from rabbit peritoneal polymorphonuclear leukocytes. Partial purification and properties. J Biol Chem 256:9583–9592
Needleman P (1978) Characterization of the reaction sequence involved in phospholipid labeling and deacylation and prostaglandin synthesis and actions. J Allergy Clin Immunol 62:96–102
Needleman P, Key SC, Isakson PC, Kulkarni PS (1975) Relationship between oxygen tension, coronary vasodilatation and prostaglandin biosynthesis in the isolated heart. Prostaglandins 9:123–134
Needleman P, Moncada S, Bunting S, Vane JR, Hamberg M, Samuelsson B (1976) Identification of an enzyme in platelet microsomes which generates thromboxane A2 from prostaglandin endoperoxides. Nature 261:558–560
Needleman P, Kulkarni PS, Raz A (1977) Coronary tone modulation: Formation and actions of prostaglandins, endoperoxides and thromboxanes. Science 195:409–412
Needleman P, Raz A, Minkes MS, Ferendelli JA, Sprecher H (1979) Triene prostaglandins: prostacyclin and thromboxane biosynthesis and unique biological properties. Proc Natl Acad Sci USA 76:944–948
Neri Serneri GG (1984) Prostaglandins and ischemic heart disease (Abstr). In: Neri Serneri GG, Masotti G, Gensini GF (eds) Platelets, prostaglandins and the cardiovascular system. Boehringer-Ingelheim, Florence, pp 20–21
Neri-Serneri GG, Gensini GF, Abbate R, Mugnaini C, Favilla S, Brunelli C, Chierchia S, Parodi O (1981a) Increased fibrinopeptide A formation and thromboxane A2 production in patients with ischemic heart disease: relationships to coronary pathoanatomy, risk factors, and clinical manifestations. Am Heart J 101:185–194
Neri Serneri GG, Masotti G, Gensini GF, Abbate R, Poggesi L, Galanti G, Favilla S (1981b) Prostacyclin, thromboxane, and ischemic heart disease. In: Johnsson Hegyeli R (ed) Prostaglandins and cardiovascular disease. Raven, New York, pp 139–157
Neri Serneri GG, Masotti G, Poggesi L, Galanti G, Morettini A, Scarti L (1982) Reduced prostacyclin production in patients with different manifestations of ischemic heart disease. Am J Cardiol 49:1146–1151
Neri Serneri GG, Abbate R, Gensini GF, Panetta A, Casolo GC, Carini M (1983) TXA2 production by human arteries and veins. Prostaglandins 25:753–766
Neri Serneri GG, Gensini GF, Abbate R, Prisco D, Rogasi PG, Casolo GC, Di Donato M, Dabizzi MP, Fantini F (1984a) Abnormal cardiopulmonary synthesis of thromboxane A2 in patients with spontaneous angina (Abstr). In: Neri Serneri GG, Masotti G, Gensini GF (eds) Platelets prostaglandins and the cardiovascular system. Bohringer-Ingelheim, Florence, pp 109–111
Neri Serneri GG, Gensini GF, Masotti G, Abbate R, Morettini A, Poggesi L, Fortini A (1984b) Role of prostacyclin and thromboxane A2 in ischemic heart disease. Adv Exp Med Biol 164:175–185
Nijkamp FP, Moncada S, White HL, Vane JR (1977) Diversion of prostaglandin endoperoxide metabolism by selective inhibition of thromboxane A2 biosynthesis in lung, spleen or platelets. Eur J Pharmacol 44:179–186
Nowak J, Kaijser L, Wennmalm A (1980) Cardiac synthesis of prostaglandins from arachidonic acid in man. Prostaglandins Med 4:205–214
Nugteren DH (1975) Arachidonate lipoxygenase in blood platelets. Biochim Biophys Acta 380:299–307
Nugteren DH, Hazelhof E (1973) Isolation and properties of intermediates in prostaglandin biosynthesis. Biochim Biophys Acta 326:448–461
Nugteren DH, van Dorp DA, Bergström S, Hamberg M, Samuelsson B (1966) Absolute configuration of the prostaglandins. Nature 212:38–39
O'Flaherty JT, Lees CJ, Stimler NP (1981) Anaphylatoxic polymorphonuclear neutrophil (PMN)-stimulating actions of platelet activating factor (PAF). Fed Proc 40:1015p
Ogawa K, Ito T, Enomoto I, Hashimoto H, Kai I, Satake T (1980) Increase of coronary flow and levels of PGE1 and PGF2α from the ischemic area of experimental myocardial infarction. Adv Prostaglandin Thromboxane Res 7:665–669
Ogawa K, Sakai K, Ito T, Watanabe J, Satake T (1983) Effects of selective thromboxane synthetase inhibitor and indomethacin on prostacyclin and thromboxane A2 from ischemic canine heart. Adv Prostaglandin Thromboxane Leukotriene Res 11:371–376
Ogino N, Miyamoto T, Yamamoto S, Hayaishi O (1977) Prostaglandin endoperoxide E isomerase from bovine vesicular gland microsomes, a glutathione-requiring enzyme. J Biol Chem 252:890–895
Ogletree ML, Lefer AM (1976) Influences of nonsteroidal anti-inflammatory agents on myocardial ischemia in the cat. J Pharmacol Exp Ther 197:582–593
Ogletree ML, Smith JB, Lefer AM (1978) Actions of prostaglandins on isolated perfused cat coronary arteries. Am J Physiol 235:H400–H406
Ogletree ML, Lefer AM, Smith JB, Nicolaou KC (1979) Studies on the protective effect of prostacyclin in acute myocardial ischemia. Eur J Pharmacol 56:95–103
O'Grady J, Warrington S, Moti MJ, Bunting S, Flower R, Fowle ASE, Higgs EA, Moncada S (1980) Effects of intravenous infusion of prostacyclin (PGI2) in man. Prostaglandins 19:319–332
Ohki S, Ogino N, Yamamoto S, Hayashi O (1979) Prostaglandin hydroperoxidase, an integral part of prostaglandin endoperoxide synthetase from bovine vesicular gland microsomes. J Biol Chem 254:829–836
Ohlendorf R, Perzborn E, Schrör K (1980) Prevention of infarction-induced decrease in circulating platelet count by prostacyclin. Thromb Res 19:447–453
Oliva PB (1983) The role of coronary artery spasm in acute myocardial infarction. Cardiovasc Clin 14:45–58
Orange RP, Austen KF (1969) Slow reacting substance of anaphylaxis. Adv Immunol 10:105–144
Osher J, Lang TW, Meerbaum S, Hashimoto K, Farcot JC, Corday E (1976) Methylprednisolone treatment in acute myocardial infarction. Effect on regional and global myocardial function. Am J Cardiol 37:564–571
Palmblad J, Malmsten CL, Udén A, Rådmark O, Engstedt L, Samuelsson B (1981) Leukotriene B4 is a potent and stereospecific stimulator of neutrophil chemotaxis and adherence. Blood 58:658–661
Panzenbeck MJ, Kaley G (1983) Leukotriene D4 reduces coronary blood flow in the anaesthetized dog. Prostaglandins 25:661–670
Patrignani P, Filabozzi P, Patrono C (1982) Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 69:1366–1372
Petsas AA, Kotler MN (1973) Electrocardiographic changes associated with penicillin anaphylaxis. Chest 64:66–69
Persantine-Aspirin Reinfarction Study Research Group (1980) Persantine and aspirin in coronary heart disease. Circulation 62:449–461
Peskar BA, Steffens Ch, Peskar BM (1979) Radioimmunoassay of 6-keto-prostaglandin F1α in biological material. In: Albertini A, Da Prada M, Peskar BA (eds) Radio-immunoassay of drugs and hormones in cardiovascular medicine. Elsevier/North-Holland, Amsterdam, pp 239–250
Peskar BA, Aehringhaus U, Weinerowski P, Wittmann G (1984) Pharmacological modification of leukotriene release and coronary constrictor effect in cardiac anaphylaxis (Abstr). In: Neri Serneri GG, Masotti G, Gensini GF (eds) Platelets prostaglandins and the cardiovascular system. Boehringer-Ingelheim, Florence, p C1
Pifer DD, Cagen LM, Chesney CM (1981) Stability of prostaglandin I2 in human blood. Prostaglandins 21:165–175
Piper PJ (1983) Pharmacology of leukotrienes. Br Med Bull 39:255–259
Piper PJ, Vane J (1971) The release of prostaglandins from lung and other tissues. Ann NY Acad Sci 180:363–383
Piper PJ, Letts LG, Samhoun MN, Tippins JR, Palmer MA (1982) Actions of leukotrienes on vascular, airway and gastrointestinal smooth muscle. In: Samuelsson B, Paoletti R (eds) Leukotrienes and other lipoxygenase products. Raven, New York, pp 169–181
Piper PJ, Letts LG, Galton SA (1983a) Generation of leukotriene like substance from porcine vascular and other tissues. Prostaglandins 25:591–599
Piper PJ, Letts LG, Tippins JR, Barnett K (1983b) Generation of a substance with the biological properties of a leukotriene from porcine vascular tissue. In: Piper PJ (ed) Leukotrienes and other lipoxygenase products. Research Studies Press, Chichester, pp 299–306
Plaut M, Lichtenstein LM (1978) Histamine, 5-hydroxytryptamine SRS-A: discussion of type I hypersensitivity (anaphylaxis). In: Vane JR, Ferreira SH (eds) Inflammation. Springer, Berlin Heidelberg New York, pp 345–373 (Handbook of Pharmacology, vol 50/1)
Ramwell PW, Leovey EMK, Sintetos AL (1977) Regulation of the arachidonic acid cascade. Biol Reprod 16:70–87
Reimer KA, Jennings RB (1979) The changing anatomic reference base of evolving myocardial infarction. Underestimation of myocardial collateral blood flow and overestimation of experimental anatomic infarct size due to tissue edema, haemorrhage and acute inflammation. Circulation 60:866–876
Ribeiro LGT, Brandon TA, Hopkins DG, Reduto LA, Taylor AA, Miller RR (1981) Prostacyclin in experimental myocardial ischemia effects on hemodynamics, regional myocardial blood flow, infarct size and mortality. Am J Cardiol 47:835–840
Roberts R, DeMello V, Sobel BE (1976) Deleterious effects of methylprednisolone in patients with myocardial infarction. Circulation (Suppl 1) 53:I204–I206
Robertson RM, Robertson D, Friesinger GC, Timmons S, Hawiger J (1980) Platelet aggregates in peripheral and coronary sinus blood in patients with spontaneous coronary artery spasm. Lancet 2:829–831
Robertson RM, Robertson D, Roberts LJ, Maas RL, FitzGerald GA, Friesinger GC, Oates JA (1981) Thromboxane A2 in vasotonic angina pectoris. Evidence for direct measurements and inhibitor trials. N Engl J Med 304:998–1003
Romson JL, Haack DW, Abrams GD, Lucchesi BR (1981) Prevention of occlusive coronary artery thrombosis by prostacyclin infusion in the dog. Circulation 64:906–914
Romson JL, Hook B, Rigot V, Swanson D, Lucchesi B (1982a) Effect of ibuprofen on the accumulation of 111-In leukocytes and platelets in infarcted dog myocardium. Fed Proc 41:8752
Romson JL, Hook B, Kunkel S, Abrams G, Lucchesi BR (1982b) Reduction of myocardial infarct size by neutrophil depletion in the dog. Circulation (Suppl 2) 66:337
Romson JL, Bush LR, Jolly SR, Lucchesi BR (1982c) Cardioprotective effects of ibuprofen in experimental regional and global myocardial ischemia. J Cardiovasc Pharmacol 4:187–196
Romson JL, Hook BG, Kunkel SL, Abrams GD, Schork MA, Lucchesi BR (1983a) Reduction of the extent of ischemic myocardial injury by neutrophil depletion in the dog. Circulation 67:1016–1023
Rosmon JL, Hook BG, Lucchesi BR (1983b) Potentiation of the antithrombotic effect of prostacyclin by simultaneous administration of aminophylline in a canine model of coronary artery thrombosis. J Pharmacol Exp Ther 227:288–294
Rösen R, Rösen P, Ohlendorf R, Schrör K (1981) Prostacyclin prevents ischemiainduced increase of lactate and cyclic AMP in ischemic myocardium. Eur J Pharmacol 69:489–491
Rösen P, Rösen R, Hohl C, Reinauer H, Klaus W (1984) Reduced transcoronary exchange and prostaglandin synthesis in diabetic rat heart. Am J Physiol 247:H563–H569
Roth DM, Lefer AM (1983) Studies on the mechanism of leukotriene induced coronary artery constriction. Prostaglandins 26:573–581
Roy L, Knapp HR, Robertson RM, FitzGerald GA (1983) Endogenous prostacyclin (PGI2) biosynthesis is stimulated by cardiac catheterization (CC) and angiography (A) in man. Circulation (Suppl 3) 68:III-104
Sakai K, Ito T, Ogawa K (1982) Role of endogenous prostacyclin and thromboxane A2 in the ischemic canine heart. J Cardiovasc Pharmacol 4:129–135
Salzman EW (1977) Interrelation of prostaglandin endoperoxide (prostaglandin G2) and cyclic 3′5′-adenosine monophosphate in human blood platelets. Biochim Biophys Acta 499:48–60
Salzman PM, Salmon JA, Moncada S (1980) Prostacyclin and thromboxane A2 synthesis by rabbit pulmonary artery. J Pharmacol Exp Ther 215:240–247
Samuelsson B (1983) Leukotrienes: Mediators of immediate hypersensitivity reactions and inflammation. Science 220:568–575
Samuelsson B, Granström E, Green K, Hamberg M, Hammarström S (1975) Prostaglandins. Annu Rev Biochem 44:669–695
Samuelsson B, Goldyne M, Granström E, Hamberg M, Hammarström S, Malmsten C (1978) Prostaglandins and thromboxanes. Annu Rev Biochem 47:997–1029
Samuelsson B, Borgeat P, Hammarström S, Murphy RC (1979) Introduction of a nomenclature: Leukotrienes. Prostaglandins 17:785–787
Sanders TAB, Naismith DJ, Haines AP, Vickers M (1980) Cod-liver oil, platelet fatty acids, and bleeding time. Lancet 1:1189
Scherhag R, Kramer HJ, Düsing R (1982) Dietary administration of eicosapentaenoic acid and linolenic acid increases arterial blood pressure and suppresses vascular prostacyclin synthesis in the rat. Prostaglandins 23:369–382
Schmidt B, Flesch I, Ecker B, Hovestadt I, Ferber E (1984) Membrane phospholipid changes during macrophage activation. Agents Actions 15:21–27
Scholtholt J, Birringer H, Fiedler VB, Schölkens B (1981) Effect of prostacyclin (PGI2) and adenosine (ASN) on total and regional blood flow of isolated, collateralized dog hearts. Basic Res Cardiol 76:313–327
Schrör K (1978) Prostaglandin D2 (PGD2) — a potent coronary vasoconstrictor agent in the guinea pig isolated heart. Naunyn Schmiedebergs Arch Pharmacol 302:61–62
Schrör K, Krebs R (1976) On the action of PGE2 on coronary vessels. A comparative study with adenosine. Naunyn Schmiedebergs Arch Pharmacol 293:R27
Schrör K, Moncada S (1979) Effects of prostacyclin on coronary circulation, heart rate and myocardial contractile force in isolated hearts of guinea pig and rabbit — comparison with prostaglandin E2. Prostaglandins 17:367–373
Schrör K, Rösen P (1979) Prostacyclin (PGI2) decreases the cyclic AMP level in coronary arteries. Naunyn Schmiedebergs Arch Pharmacol 306:101–103
Schrör K, Moncada S, Ubatuba FB, Vane JR (1978) Transformation of arachidonic acid and prostaglandin endoperoxides by the guinea pig heart. Formation of RCS and prostacyclin. Eur J Pharmacol 47:103–114
Schrör K, Link HB, Rösen R, Klaus W, Rösen P (1980a) Prostacyclin-induced coronary vasodilatation. Interactions with adenosine, cyclic AMP, and energy charge in the rat heart in vitro. Eur J Pharmacol 64:341–348
Schrör K, Rösen P, Link HB, Rösen P (1980b) Physiological and biochemical parameters of prostacyclin action on the heart and the coronary vasculature. Adv Prostaglandin Thromboxane Res 7:625–630
Schrör K, Addicks K, Darius H, Ohlendorf R, Rösen P (1981a) PGI2 inhibits ischemiainduced platelet activation and prevents myocardial damage by inhibition of catecholamine release from adrenergic nerve terminals. Evidence for cAMP as common denominator. Thromb Res 21:175–180
Schrör K, Grodzinska L, Darius H (1981b) Stimulation of coronary vascular prostacyclin and inhibition of human thromboxane A2 after low-dose-nitroglycerin. Thromb Res 23:59–67
Schrör K, Köhler P, Müller M, Peskar BA, Rösen P (1981c) Prostacyclin-thromboxane interactions in the platelet-perfused in vitro heart. Am J Physiol 241:H18–H25
Schrör K, Ohlendorf R, Darius H (1981d) Beneficial effects of a new carbacyclin derivative, ZK 36374, in acute myocardial ischemia. J Pharmacol Exp Ther 219:243–249
Schrör K, Darius H, Ohlendorf R, Matzky R, Klaus W (1982) Dissociation of antiplatelet effects from myocardial cytoprotective activity during acute myocardial ischemia in cats by a new carbacyclin derivative (ZK 36374). J Cardiovasc Pharmacol 4:554–561
Schumacher WA, Lucchesi BR (1983) Effect of thromboxane synthetase inhibitor UK-37,248 (dazoxiben) upon platelet aggregation, coronary artery thrombosis and vascular reactivity. J Pharmacol Exp Ther 227:790–796
Schwartz CJ (1982) Thrombosis in the pathogenesis of sudden cardiac death and myocardial infarction. In: Oates JA (ed) Prostaglandins and the cardiovascular system. Raven, New York, pp 1–14
Scott-Miller AM, McMillan RM (1983) Aggregation and degranulation in human neutrophils: Do lipoxygenase metabolites play a role? In: Piper PJ (ed) Leukotrienes and other lipoxygenase products. Research Studies Press, Chichester, pp 255–256
Shaw JO, Printz MP, Hirabayashi K, Henson PM (1978) Role of prostaglandin synthesis in rabbit platelet activation induced by basophil-derived platelet-activating factor. J Immunol 121:1939–1945
Shaw JO, Klusick SJ, Hanahan DJ (1981) Activation of rabbit platelet phospholipase and thromboxane synthesis by 1-O-hexadecyl/octadecyl-2-acetyl-sn-glyceryl-3-phosphorylcholine (platelet activating factor). Biochim Biophys Acta 663:222–229
Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR (1984a) Effect of OKY-1581, a thromboxane synthetase inhibitor, on coronary thrombosis in the conscious dog. Eur J Pharmacol 105:285–291
Shea MJ, Driscoll EM, Romson JL, Pitt B, Lucchesi BR (1984b) The beneficial effects of nafazatrom (BAYg6575) on experimental coronary thrombosis. Am Heart J 107:629–637
Sherry S (1982) Effect of prostaglandin-mediated platelet-suppressant drugs on acute cardiovascular catastrophes. In: Oates JA (ed) Prostaglandins and the cardiovascular system. Raven, New York, pp 173–210
Sherry S (1983) Role of platelet-active drugs in coronary artery disease. Cardiovasc Clin 14:173–189
Shimamoto T (1978) Stroke and heart attack induced experimentally by thromboxane A2 in rabbits and effect of EG 626, a thromboxane A2 antagonist. In: Wissler RW et al. (eds) International Symposium: State of prevention and therapy in human artherosclerosis and in animal models. Westdeutscher Verlag, Colognes, pp 139–152
Siess W, Roth P, Scherer B, Kurzmann I, Böhlig B, Weber PC (1980) Platelet-membrane fatty acids, platelet aggregation, and thromboxane formation during a mackerel diet. Lancet 1:441–444
Silberbauer K, Schernthaner G, Sinzinger H, Piza-Katzer H, Winter M (1979) Decreased vascular prostacyclin in juvenile-onset diabetes. N Engl J Med 300:366–367
Sinzinger H, Feigl W, Silberbauer K (1979) Prostacyclin generation in atherosclerotic arteries. Lancet 2:469
Sinzinger H, Scherntaner G, Kaliman J (1981) Sensitivity of platelets to prostaglandins in coronary heart disease and angina pectoris. Prostaglandins 22:773–781
Sinzinger H, O'Grady J, Fitscha P, Kaliman J (1984) Extremely-low-dose aspirin (one milligram per day) renders human platelets more sensitive to antiaggregation prostaglandins. N Engl J Med 311:1052
Smirnov IE, Mentz PR, Markov CM (1980) Effects of prostacyclin on coronary blood flow and cardiac activity in normotensive and spontaneously hypertensive rats. Adv Prostaglandin Thromboxane Res 7:631–633
Smith EF III, Lefer AM (1981) Stabilization of cardiac lysosomal and cellular membranes in protection of ischemic myocardium due to coronary occlusion: Efficacy of the nonsteroidal anti-inflammatory agent, naproxen. Am Heart J 101:394–402
Smith EF III, Carrow BA, Lefer AM (1980) Effects of flurbiprofen on myocardial cell damage during acute myocardial ischemia. Res Commun Chem Pathol Pharmacol 28:413–433
Smith EF III, Lefer AM, Nicolaou KC (1981a) Mechanisms of coronary vasoconstriction induced by carbocylic thromboxane A2. Am J Physiol 240:H493–497
Smith EF III, Lefer AM, Aharony D, Smith JB, Magolda RL, Claremon D, Nicolaou KC (1981b) Carbocyclic thromboxane A2: Aggravation of myocardial ischemia by a new synthetic thromboxane A2 analog. Prostaglandins 21:443–456
Smith EF III, Gallenkämper W, Beckmann R, Thomsen T, Mannesmann G, Schrör K (1984) Early and late administration of a PGI2-analogue, ZK36374 (iloprost): effects on myocardial preservation, collateral blood flow and infarct size. Cardiovasc Res 18:163–173
Smith JB, Jubiz W (1981) OKY-1581: a selective inhibitor of thromboxane synthesis in vivo and in vitro. Prostaglandins 22:353–363
Smith JB, Willis AL (1971) Aspirin selectively inhibits prostaglandin production in human platelets. Nature (New Biol) 231:235–237
Smith WL, Lands WEM (1972) Oxygenation of polyunsaturated fatty acids during prostaglandin biosynthesis by sheep vesicular gland. Biochemistry 11:3276–3285
Smitherman TC, Milam M, Woo J, Willerson JT, Frenkel EP (1981) Elevated beta thromboglobulin in peripheral venous blood of patients with acute myocardial ischemia: direct evidence for enhanced platelet reactivity in vivo. Am J Cardiol 48:395–402
Sobel BE, Corr PB (1979) Biochemical mechanisms potentially responsible for lethal arrhythmias induced by ischemia: the lysolipid hypothesis. Adv Cardiol 26:76–85
Sommers HM, Jennings RB (1964) Experimental acute myocardial infarction. Histologic and histochemical studies of early myocardial infarcts induced by temporary or permanent occlusion of a coronary artery. Lab Invest 13:1491–1503
Spath JA, Lane DL, Lefer AM (1974) Protective action of methylprednisolone on the myocardium during experimental myocardial ischemia in the cat. Circ Res 35:44–51
Spector AA, Kaduce TL, Figard PH, Norton KC, Haak JC, Czervionke RL (1983) Eicosapentaenoic acid and prostacyclin production by cultured human endothelial cells. J Lipid Res 24:1595–1604
Stein I, Wecksell I (1970) Cardiac disease accompanying allergic drug reactions. J Allergy 45:48–54
Stimler NP, Bloor CM, Hugli TE, Wykle RL, McCall CE, O'Flaherty JT (1981) Anaphylactic actions of platelet-activating factor. Am J Pathol 105:64–69
Struijck CB, Beerthuis RL, Pabon HJJ, Van Dorp DA (1966) specificity of the enzyme conversion of polyunsaturated fatty acids into prostaglandins. Recl Trav Chim Pays Bas 85:1233–1250
Subbiah MTR, Deitemeyer D (1980) Altered synthesis of prostaglandins in platelet and aorta from spontaneously diabetic Wistar rats. Biochem Med 23:231–235
Sun FF (1977) Biosynthesis of thromboxanes in human platelets. I. Characterization and assay of thromboxane synthetase. Biochem Biophys Res Commun 74:1432–1440
Svensson J, Hamberg M (1976) Thromboxane A2 and prostaglandin H2: Potent stimulators of the swine coronary artery. Prostaglandins 12:943–950
Svensson J, Hamberg M, Samuelsson B (1975) Prostaglandin endoperoxides IX. Characterization of rabbit aorta contracting substance (RCS) from guinea pig lung and human platelets. Acta Physiol Scand 94:222–228
Szczeklik A, Gryglewski RJ (1980) Low density lipoproteins (LDL) are carriers for lipid peroxides and invalidate prostacyclin (PGI2) biosynthesis in arteries. Artery 7:488–495
Szczeklik A, Gryglewski RJ, Musial J, Grodzinska L, Serwónska M, Marcinkiewicz E (1978a) Thromboxane generation and platelet aggregation in survivals of myocardial infarction. Thromb Haemost 40:66–74
Szczeklik A, Gryglewski RJ, Nizánkowski R, Musial J, Pieton R, Mruk J (1978b) Circulatory and antiplatelet effects of intravenous prostacyclin in healthy man. Pharmacol Res Commun 10:545–556
Szczeklik A, Szczeklik J, Nizankowski R, Gluszko P (1980) Prostacyclin for acute coronary insufficiency. Artery 8:7–11
Szczeklik A, Gryglewski RJ, Domagala B, Zmuda A, Hartwich J, Wozny E, Grzywacz M, Madej J, Gryglewska T (1981) Serum lipoproteins, lipid peroxides and prostacyclin biosynthesis in patients with coronary heart disease. Prostaglandins 12:795–807
Tada M, Kuzuya T, Inoue M, Kodama K, Mishima M, Yamada M, Inui M, Abe H (1981) Elevation of thromboxane B2 levels in patients with classic and variant angina pectoris. Circulation 64:1107–1115
Tanabe M, Terashita ZI, Fujiwara S, Shimamoto N, Gota N, Nishikawa K, Hirata M (1982) Coronary circulatory failure and thromboxane A2 release during coronary occlusion and reperfusion in anaesthetized dogs. Cardiovasc Res 16:99–106
Tappel AL, Lundberg WO, Boyer PD (1953) Effect of temperature and antioxidants upon the lipoxidase-catalyzed oxidation of sodium linoleate. Arch Biochem Biophys 42:293–304
Tateson JE, Moncada S, Vane JR (1977) Effect of prostacyclin (PGX) on cyclic AMP concentrations in human platelets. Prostaglandins 13:389–397
Taylor GW, Morris HR (1983) Lipoxygenase pathways. Br Med Bull 39:219–222
Terano T, Salmon JA, Moncada S (1984a) Biosynthesis and biological activity of leukotriene B5. Prostaglandins 27:217–232
Terano T, Salmon JA, Moncada S (1984b) Effect of orally administered eicosapentaenoic acid (EPA) on the formation of leukotriene B4 and leukotriene B5 by rat leukocytes. biochem Pharmacol 33:3071–3076
Terashita ZI, Fukui H, Nishikawa K, Hirata M, Kikuchi S (1978) Coronary vasospastic action of thromboxane A2 in isolated, working guinea pig hearts. Eur J Pharmacol 53:49–56
Terashita ZI, Fukui H, Hirata M, Terao S, Ohkawa S, Nishikawa K, Kikuchi S (1981) Coronary vasoconstriction and PGI2 release by leukotrienes in isolated guinea pig hearts. Eur J Pharmacol 73:357–361
Thaulow E (1983) Platelet function in blood from the coronary sinus in patients with arteriosclerotic heart disease. Thromb Haemost 50:629–632
Thaulow E, Dale J, Myhre E (1984) Effects of a selective thromboxane synthetase inhibitor, dazoxiben, and of acetylsalicylic acid on myocardial ischemia in patients with coronary artery disease. Am J Cardiol 53:1255–1258
Toda N (1984) Responses of human, monkey and dog coronary arteries in vitro to carbocyclic thromboxane A2 and vasodilators. Br J Pharmacol 83:399–408
Trachte GJ, Lefer AM, Aharony D, Smith JB (1979) Potent constriction of cat coronary arteries by hydroperoxides of arachidonic acid and its blockade by anti-inflammatory agents. Prostaglandins 18:909–914
Tremoli E, Folco GC, Agradi E, Galli C (1979) Platelet thromboxanes and serum cholesterol. Lancet 1:107–108
Tremoli E, Maderna P, Collis S, Morazzoni G, Sirtori M, Sirtori CR (1984) Increased platelet sensitivity and thromboxane B2 formation in type II hyperlipoproteinaemic patients. Eur J Clin Invest 14:329–333
Turner SR, Tainer JA, Lynn WS (1975) Biogenesis of chemotactic molecules by the arachidonate lipoxygenase system of platelets. Nature 257:680–681
Tuvemo T, Strandberg K, Hamberg M, Samuelsson B (1976) Maintenance of the tone of the human umbilical artery by prostaglandin and thromboxane formation. Adv Prostaglandin Thromboxane Res 1:425–428
Tyler HM, Saxton CAPD, Parry MJ (1981) Administration to man of UK-37,248-01, a selective inhibitor of thromboxane synthetase. Lancet 1:629–632
Ubatuba FB, Moncada S, Vane JR (1979) The effect of prostacyclin (PGI2) on platelet behaviour, thrombus formation in vivo and bleeding time. Thromb Haemost 41:425–435
Uchida Y, Hanai T, Hasegawa K, Kawamura K, Oshima T (1983) Recanalization of obstructed coronary artery by intracoronary administration of prostacyclin in patients with acute myocardial infarction. Adv Prostaglandin Thromboxane Leukotriene Res 11:377–383
Van der Giessen WJ, Serruys PW, Stoel I, Hugenholtz PG, de Leeuw PW, van Vliet HHDM, Deckmyn H, Vermylen J (1983) Acute effect of cigarette smoking on cardiac prostaglandin synthesis and platelet behaviour in patients with coronary heart disease. Adv Prostaglandin Thromboxane Leukotriene Res 11:359–364
Van der Ouderaa FJ, Buytenhek M, Nugteren DH, Van Dorp DA (1977) Purification and characterization of prostaglandin endoperoxide synthetase from sheep vesicular glands. Biochim Biophys Acta 487:315–331
Van Dorp DA (1966) The biosynthesis of prostaglandins. Mem Soc Endocrinol 14:39–47
Van Dorp DA, Beerthuis RK, Nugteren DH, Vonkeman H (1964) The biosynthesis of prostaglandins. Biochim Biophys Acta 90:204–207
Vane JR (1971) Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature (New Biol) 231:232–235
Vermylen J, Chamone DAF, Verstraete M (1979) Stimulation of prostacyclin release from vessel wall by BAYg6575, an antithrombotic compound. Lancet 1:518–520
Vesterqvist O, Gréen K (1984) Urinary excretion of 2,3-dinor-thromboxane B2 in man under normal conditions, following drugs and during some pathological conditions. Prostaglandins 27:627–644
Voelkel NF, Worthen S, Reeves JT, Henson PM, Murphy RC (1982) Nonimmunological production of leukotrienes induced by platelet-activating factor. Science 218:286–288
Vogel WM, Zannoni VG, Abrams GD, Lucchesi BR (1977) Inability of methylprednisolone sodium succinate to decrease infarct size or preserve enzyme activity measured 24 hours after coronary occlusion in the dog. Circulation 55:588–595
Vogt W (1978) Role of phospholipase A2 in prostaglandin formation. Adv Prostaglandin Thromboxane Res 3:89–95
Von Euler US (1934) Zur Kenntnis der pharmakologischen Wirkungen von Nativsekretion und Extrakten männlicher akzessorischer Geschlechtsdrüsen. Arch Exp Pathol Pharmakol 175:78–84
Von Euler US (1935) Über die spezifische blutdurcksenkende Substanz des menschlichen Prostata-und Samenblasensekretes. Klin Wochenschr 33:1182–1183
Von Euler US (1937) On the specific vaso-dilating and plain muscle stimulating substances from accessory genital glands in man and certain animals (prostaglandin and vesiglandin). J Physiol (Lond) 88:213–234
Vonkeman H, van Dorp DA (1968) The action of prostaglandin synthetase on 2-arachidonyl-lecithin. Biochim Biophys Acta 164:430–432
Wallis J, Moses JW, Borer JS, Weksler B, Goldberg HL, Fisher J, Kase M, Tack-Goldman K, Carter J, Calle S (1982) Coronary blood flow in coronary artery disease: heparin-induced potentiation caused by prostaglandin release. Circulation (Suppl 2) 66:II-263
Wang HH, Kulkarni PS, Eakins KE (1980) Effect of prostaglandins and thromboxane A2 on the coronary circulation of adult dogs and puppies. Eur J Pharmacol 66:31–41
Warrington SJ, O'Grady J (1980) Cardiovascular effects of prostacyclin in man. Adv Prostaglandin Thromboxane Res 7:619–624
Weiss ES, Ahmed SA, Thakur ML, Welch MJ, Coleman RE, Sobel BE (1977) Imaging of the inflammatory response in ischemic canine myocardium with 111-indium-labelled leukocytes. Am J Cardiol 40:195–199
Weksler BB, Marcus AJ, Jaffe EA (1977) Synthesis of prostaglandin I (prostacyclin) by cultured human and bovine endothelial cells. Proc Natl Acad Sci USA 74:3922–3926
Welman E, Selwyn AP, Fox KM (1979) Lysosomal and cytosolic enzyme release in acute myocardial infarction: effects of methylprednisolone. Circulation 59:730–733
Welton AF, Hope WC, Tobias LD, Hamilton JG (1981) Inhibition of antigen induced histamine release and thromboxane synthetase by FPL 55712. A specific SRS-A antagonist? Biochem Pharmacol 30:1378–1382
Weltzien HU (1979) Cytolytic and membrane-perturbing properties of lysophosphatidylcholine. Biochim Biophys Acta 559:259–287
Wennmalm Å (1979) Prostaglandin-mediated inhibition of noradrenaline release. VI. On the intra-cardiac source of prostaglandins released from isolated rabbit hearts. Acta Physiol Scand 105:254–256
Wennmalm Å (1980) Nicotine inhibits hypoxia-and arachidonate-induced release of prostacyclin-like activity in rabbit hearts. Br J Pharmacol 69:545–549
Wennmalm Å (1982) Interaction of nicotine and prostaglandins in the cardiovascular system. Prostaglandins 23:139–144
Wennmalm Å (1984) Prostacyclin (PGI2) mediates the coronary vasodilator effect of adenosine (Abstr). In: Neri Serneri GG, Masotti G, Gensini GF (eds) Platelets prostaglandins and the cardiovascular system. Boehringer-Ingelheim, Florence, p 200
Wennmalm Å, Henriksson P, Ehag O (1984) Limitation of myocardial infarct size in humans with prostacyclin (Abstr). In: Neri Serneri GG, Masotti G, Gensini GF (eds) Platelets prostaglandins and the cardiovascular system. Boehringer-Ingelheim, Florence, p 166
Went S, Lissák K (1935) Histamin-und Proteinwirkung am normalen und sensibilisierten Meerschweinchenherz. Naunyn Schmiedebergs Arch Exp Pathol Pharmakol 179:609–615
Whittle BJR, Moncada S (1983) Pharmacological interactions between prostacyclin and thromboxanes. Br Med Bull 39:232–238
Whittle BJR, Moncada S, Vane JR (1978) Comparison of the effects of prostacyclin (PGI2) prostaglandin E1 and D2 on platelet aggregation in different species. Prostaglandins 16:373–388
Whittle BJR, Moncada S, Whiting F, Vane JR (1980) Carbacyclin — a potent stable prostacyclin analogue for the inhibition of platelet aggregation. Prostaglandins 19:605–627
Wilcox HB, Andrus EC (1938) Anaphylaxis in the isolated heart. J Exp Med 67:169–180
Wilkerson RD, Conran PB (1982) Ibuprofen reduces infarct size and ventricular arrhythmias after coronary occlusion (CAO). Fed Proc 41:1737
Wittenberg HR, Wölbling RH, Aehringhaus U, Patrono C, Peskar BM, Peskar BA (1983) Release of slow-reacting substance of anaphylaxis from guinea pig heart and vascular tissue. In: Piper PJ (ed) Leukotrienes and other lipoxygenase products. Research Studies Press, Chichester, pp 121–127
Wittmann G, Weinerowski P, Aehringhaus U, Peskar BA (1984) Effect of muscarinic receptor stimulation and of prostaglandins (PG) on release of leukotriene C4 (LTC4)-like immunoreactivity in cardiac anaphylaxis. Naunyn Schmiedebergs Arch Pharmacol (Suppl) 325:R36
Wlodawer P, Hammarström S (1978) Thromboxane synthetase from bovine lung — solubilization and partial purification. Biochem Biophys Res Commun 80:525–532
Wölbling RH, Aehringhaus U, Peskar BM, Peskar BA (1983) Release of slow reacting substance of anaphylaxis from layers of guinea pig aorta. Prostaglandins 25:823–828
Woodman OL, Dusting GJ (1983) Coronary vasoconstriction induced by leukotrienes in the anaesthetized dog. Eur J Pharmacol 86:125–128
Wynalda MA, Fitzpatrick FA (1980) Albumins stabilize prostaglandin I2. Prostaglandins 20:853–861
Yoshimoto T, Yamamoto S, Okuma M, Hayaishi O (1977) Solubilization and resolution of thromboxane synthesizing system from microsomes of bovine blood platelets. J Biol Chem 252:5871–5874
Yui Y, Hattori R, Takatsu Y, Nakajima H, Wakabayashi A, Kawai C, Kayama N, Hiraku S, Inagawa T, Tsubojima M, Naito J (1984) Intravenous infusion of a selective inhibitor of thromboxane A2 synthetase in man: influence on thromboxane B2, and 6-keto-prostaglandin F1α levels and platelet aggregation. Circulation 70:599–605
Zavecz JH, Levi R (1977) Separation of primary and secondary cardiovascular events in systemic anaphylaxis. Circ Res 40:15–19
Ziboh VA, Maruta H, Lord J, Cagle WD, Lucky W (1979) Increased biosynthesis of thromboxane A2 in diabetic platelets. Eur J Clin Invest 9:223–228
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1986 Springer-Verlag
About this chapter
Cite this chapter
Simmet, T., Peskar, B.A. (1986). Eicosanoids and the coronary circulation. In: Reviews of Physiology, Biochemistry and Pharmacology, Volume 104. Reviews of Physiology, Biochemistry and Pharmacology, vol 104. Springer, Berlin, Heidelberg. https://doi.org/10.1007/BFb0031012
Download citation
DOI: https://doi.org/10.1007/BFb0031012
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-15940-7
Online ISBN: 978-3-540-39672-7
eBook Packages: Springer Book Archive